

xx New interleukin-1 receptor analog SIGIRR nucleic acid and proteins

xx Claim 2; Page 69-71; 72pp; English.

cc This invention describes a novel human SIGIRR DNA, its allelic variants
cc or species homologues which have anti-inflammatory and anti-autimmune
cc disease activity. SIGIRR is an analog of interleukin-1 receptor. The
cc products of the invention are used (a) as probes or primers for
cc identifying nucleic acid that encodes proteins with SIGIRR activity; (b)
cc to identify human chromosome 11, to map genes on this chromosome and to
cc identify disease-related genes (particularly in the region 11p15.5 where
cc genes are present associated with e.g. arthrogryposis multiplex
cc congenita, breast cancer, insulin-dependent diabetes, sickle cell
cc anaemia, bladder cancer), including detection of defective genes; (c)
cc to study cell-signal transduction and the SIGIRR system, and (d) in
cc gene therapy. Sense and antisense oligonucleotides can be used to inhibit
cc expression of the SIGIRR gene. The proteins of the invention are used:
cc (i) to study cellular processes (immune regulation, proliferation, death,
cc migration, interaction with other cells and inflammation); (ii) to
cc identify and purify proteins that associate with SIGIRR ligands and
cc receptors, and to measure their biological activity; (iii) in screening
cc for and rational design of, potential inhibitors of activity; (iv)
cc therapeutically against diseases mediated by SIGIRR polypeptide
cc counter-structures; (v) as molecular weight (m.w.) markers in
cc electrophoresis; (vi) for determining isoelectric points of unknown
cc proteins; (vii) as controls for determining the extent of protein
cc fragmentation (e.g. to aid characterization of protein structures by
cc mass spectrometry); (viii) for generation of antibodies (Ab); (ix) to
cc deliver diagnostic or therapeutic agents to cells that express SIGIRR
cc binding molecules.

xx Sequence 410 AA;

xx Query Match 100.0%; Score 626; DB 20; Length 410;

xx Best Local Similarity 100.0%; Pred. No. 1.6e-57;

xx Matches 118; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPGVCDRAPDLPSEDDVLRPALGSSVALNCTAWVSGPHCSLPSONMLKDLPLGIGG 60

Db 1 MPGVCDRAPDLPSEDDVLRPALGSSVALNCTAWVSGPHCSLPSONMLKDLPLGIGG 60

Qy 61 HYSLHEYSWKANLSEVLYSSVLGVNVTSTEVYGAFTCSIONISFSFTLORAGPTSH 118

Db 61 HYSLHEYSWKANLSEVLYSSVLGVNVTSTEVYGAFTCSIONISFSFTLORAGPTSH 118

RESULT 2

AAB61139 standard; Protein: 410 AA.

AAB61139;

30-MAR-2001 (first entry)

Human NOV9 protein.

Human: NOV9; antiinflammatory; cytosolic; neuroprotective;
cerebroprotective; immunomodulator; vulnerrary; vasotropic; gene therapy;
hyperplasia; tumour; restenosis; psoriasis; Dupuytren's contracture;
diabetes; rheumatoid arthritis; cerebral oedema; Alzheimer's disease.

Homo sapiens.

OS

PN WO200075321-A2

14-DEC-2000.

01-JUN-2000; 2000WO-US15303.

03-JUN-1999; 99US-0137322.

16-MAR-2000; 2000US-0189810.

22-MAR-2000; 2000US-0191158.

PR 30-MAR-2000; 2000US-0193086.

PR 31-MAY-2000; 2000US-0137322.

PR (CURA-) CURAGEN CORP.

PR Shinkets RA, Fernandes E, Herrman J, Vernet C;

PR WPI: 2001-102403/11.

PR N-PDSB; AAF27857.

xx New NOVX polypeptides and polynucleotides, useful in gene therapy, as a
xx diagnostic marker, protein therapeutic, antibody or small molecule drug
xx target for treating immune, proliferative and metabolic diseases and
xx wound healing

xx Claim 1; Page 36-38; 194pp; English.

cc The present sequence is a new isolated polypeptide (NOVX). The NOVX
cc polypeptides, NOVX nucleic acids, and anti-NOVX antibodies are useful for
cc treating or preventing NOVX-associated disorders. They are also useful
cc for determining the presence of or a predisposition to a disease
cc associated with altered levels of the NOVX polypeptide or nucleic acid.
cc These NOVX-associated disorders include hyperplasias, tumours,
cc rheumatoid arthritis, cerebral lesions, diabetic neuropathies, cerebral
cc oedema, senile dementia or Alzheimer's disease. The NOVX polynucleotides
cc are especially useful in gene therapy. Specifically, NOVX is useful as
cc a diagnostic marker or prognostic marker, protein therapeutic and
cc antibody target or small molecule drug target to treat disorders in the
cc immune response pathway, thyroid and metabolic diseases, bone metabolic
cc disorders, diseases of the pancreas (e.g. diabetes or digestive
cc disorders), proliferative diseases, or tissue regeneration and
cc development (e.g. wound healing or treatment of burns).

xx Sequence 410 AA;

xx Query Match 100.0%; Score 626; DB 22; Length 410;

xx Best Local Similarity 100.0%; Pred. No. 1.6e-57;

xx Matches 118; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPGVCDRAPDLPSEDDVLRPALGSSVALNCTAWVSGPHCSLPSONMLKDLPLGIGG 60

Db 1 MPGVCDRAPDLPSEDDVLRPALGSSVALNCTAWVSGPHCSLPSONMLKDLPLGIGG 60

Qy 61 HYSLHEYSWKANLSEVLYSSVLGVNVTSTEVYGAFTCSIONISFSFTLORAGPTSH 118

Db 61 HYSLHEYSWKANLSEVLYSSVLGVNVTSTEVYGAFTCSIONISFSFTLORAGPTSH 118

RESULT 3

AAU86151 standard; Protein: 504 AA.

AAU86151;

15-JUL-2002 (first entry)

Human PRO342 polypeptide.

Human: PRO; benign tumour; malignant tumour; lymphoid malignancy;
leukaemia; neuronal disorder; stromal disorder; blastocoele disorder;
inflammatory disorder; immune disorder; angiogenic disorder;
cytosolic; neuroprotective.

Homo sapiens.

OS

PN WO200153486-A1

26-JUL-2001.

11-FEB-2000; 2000WO-US03565.

08-MAR-1999; 99WO-US05028.

PR 11-MAR-1999; 99US-123972P.
PR 11-MAY-1999; 99US-133459P.
PR 02-JUN-1999; 99WO-US12252.
PR 22-JUN-1999; 99US-140650P.
PR 20-JUN-1999; 99US-140653P.
PR 20-JUL-1999; 99US-144758P.
PR 26-JUL-1999; 99US-145698P.
PR 28-JUL-1999; 99US-146222P.
PR 17-AUG-1999; 99US-149395P.
PR 31-AUG-1999; 99US-151689P.
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 05-JAN-2000; 2000WO-US00219.
XX
XX (GETH) GENENTECH INC.
PI Ashkenazi AJ, Goddard A, Godowski PJ, Gurney AL, Hillan KJ;
PI Marsters SA, Pan J, Plettl RM, Roy MA, Smith V, Stone DM;
PI Watanabe CK, Wood WI;
XX WPI: 2002-205567/26.
DR N-PSDB; ABK40277.
XX
XX Thirty five nucleic acids encoding PRO polypeptides, useful for
PT treating benign or malignant tumours, leukemias and lymphoid
PT malignancies, inflammatory, angiogenic and immunologic disorders -
PS Claim 61: Fig 48; 302pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides and the polynucleotide sequences encoding them. The
CC PRO polypeptides, agonists, antagonists or anti-PRO antibodies are
CC useful for treating benign or malignant tumours (e.g. renal, kidney,
CC bladder, breast, etc), leukemias and lymphoid malignancies, other
CC disorders such as neuronal, glial, astrocytal, hypothalamic, glandular,
CC macrophagal, stromal and blastocellic disorders, inflammatory, immune
CC and angiogenic disorders. The polynucleotide sequences are also
CC useful in gene therapy. AA086128-AA086162 represent the human PRO
CC polypeptides of the invention.
XX
XX Sequence 504 AA:
SQ
Query Match 100.0%; Score 626; DB 23; Length 504;
Test Local Similarity 100.0%; Pred. No. 2e-57;
atches 118; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 MPEVCDDRADPFLSPEDVLRPALGSSVALNCTAMVYSGPHGSLPSVOMLKDGLPIGIG 60
Db 1 MPEVCDDRADPFLSPEDVLRPALGSSVALNCTAMVYSGPHGSLPSVOMLKDGLPIGIG 60
OY 61 HYSLEHYSWKANLSEVLSSVLYGVNVTSEYVGAFTCSIQNISFSSFTLQAGPTSH 118
Db 61 HYSLEHYSWKANLSEVLSSVLYGVNVTSEYVGAFTCSIQNISFSSFTLQAGPTSH 118
RESULT 4
ID AAU17408 standard; Protein; 407 AA.
XX AAU17408;
AC AAU17408;
XX
DT 07-NOV-2001 (first entry)
XX
DE Novel signal transduction pathway protein, Seq ID 973.
XX
XX Neutropenic; cytostatic; dermatological; immunosuppressive; tumour;
KW antiinflammatory; anti-HIV; antibacterial; antiinflammatory; cancer;
KW immune system disorder; rheumatoid arthritis; inflammatory condition;
KW organ transplant rejection; infection; hepatitis C; blood disorder;
KW sickle cell anaemia; hyperproliferative disorder; Gaucher's disease;

KW neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
KW chromosomal abnormality; Down syndrome; ischaemia; renal disorder;
KW cardiovascular; respiratory; wound healing; endocrine; Addison's disease;
KW reproductive system; gastrointestinal; liver disorder; AIDS;
KW acquired immune deficiency syndrome.
XX Homo sapiens.
XX WO200154733-A1.
PN 02-AUG-2001.
PD
XX
XX 17-JAN-2001; 2001WO-US01312.
PF
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 30-JUN-2000; 2000US-0214886.
PR 28-JUL-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226881.
PR 22-AUG-2000; 2000US-0226886.
PR 23-AUG-2000; 2000US-0227182.
PR 30-AUG-2000; 2000US-0227009.
PR 01-SEP-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 06-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0232081.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.

PR 14-SEP-2000; 2000US-0233065.
 PR 21-SEP-2000; 2000US-0234223.
 PR 21-SEP-2000; 2000US-0234223.
 PR 25-SEP-2000; 2000US-0234997.
 PR 25-SEP-2000; 2000US-0234998.
 PR 26-SEP-2000; 2000US-0235484.
 PR 27-SEP-2000; 2000US-0235834.
 PR 27-SEP-2000; 2000US-0235836.
 PR 29-SEP-2000; 2000US-0236327.
 PR 29-SEP-2000; 2000US-0236367.
 PR 29-SEP-2000; 2000US-0236368.
 PR 29-SEP-2000; 2000US-0236369.
 PR 29-SEP-2000; 2000US-0236370.
 PR 02-OCT-2000; 2000US-0236802.
 PR 02-OCT-2000; 2000US-0237037.
 PR 02-OCT-2000; 2000US-0237038.
 PR 02-OCT-2000; 2000US-0237039.
 PR 02-OCT-2000; 2000US-0237040.
 PR 13-OCT-2000; 2000US-0239935.
 PR 13-OCT-2000; 2000US-0239937.
 PR 20-OCT-2000; 2000US-0240960.
 PR 20-OCT-2000; 2000US-0241221.
 PR 20-OCT-2000; 2000US-0241785.
 PR 20-OCT-2000; 2000US-0241786.
 PR 20-OCT-2000; 2000US-0241808.
 PR 20-OCT-2000; 2000US-0241809.
 PR 20-OCT-2000; 2000US-0241826.
 PR 01-NOV-2000; 2000US-0244617.
 PR 08-NOV-2000; 2000US-0246474.
 PR 08-NOV-2000; 2000US-0246475.
 PR 08-NOV-2000; 2000US-0246476.
 PR 08-NOV-2000; 2000US-0246477.
 PR 08-NOV-2000; 2000US-0246478.
 PR 08-NOV-2000; 2000US-0246523.
 PR 08-NOV-2000; 2000US-0246524.
 PR 08-NOV-2000; 2000US-0246525.
 PR 08-NOV-2000; 2000US-0246526.
 PR 08-NOV-2000; 2000US-0246527.
 PR 08-NOV-2000; 2000US-0246528.
 PR 08-NOV-2000; 2000US-0246532.
 PR 08-NOV-2000; 2000US-0246609.
 PR 08-NOV-2000; 2000US-0246610.
 PR 08-NOV-2000; 2000US-0246611.
 PR 08-NOV-2000; 2000US-0246613.
 PR 17-NOV-2000; 2000US-0249207.
 PR 17-NOV-2000; 2000US-0249208.
 PR 17-NOV-2000; 2000US-0249209.
 PR 17-NOV-2000; 2000US-0249210.
 PR 17-NOV-2000; 2000US-0249211.
 PR 17-NOV-2000; 2000US-0249212.
 PR 17-NOV-2000; 2000US-0249213.
 PR 17-NOV-2000; 2000US-0249214.
 PR 17-NOV-2000; 2000US-0249215.
 PR 17-NOV-2000; 2000US-0249216.
 PR 17-NOV-2000; 2000US-0249217.
 PR 17-NOV-2000; 2000US-0249218.
 PR 17-NOV-2000; 2000US-0249244.
 PR 17-NOV-2000; 2000US-0249245.
 PR 17-NOV-2000; 2000US-0249264.
 PR 17-NOV-2000; 2000US-0249265.
 PR 17-NOV-2000; 2000US-0249297.
 PR 17-NOV-2000; 2000US-0249299.
 PR 17-NOV-2000; 2000US-0249300.
 PR 01-DEC-2000; 2000US-0250160.
 PR 01-DEC-2000; 2000US-0250391.
 PR 05-DEC-2000; 2000US-0251030.
 PR 05-DEC-2000; 2000US-0251988.
 PR 05-DEC-2000; 2000US-0256719.
 PR 06-DEC-2000; 2000US-0251479.
 PR 08-DEC-2000; 2000US-0251856.
 PR 08-DEC-2000; 2000US-0251868.
 PR 08-DEC-2000; 2000US-0251869.

PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251990.
 PR 11-DEC-2000; 2000US-0254097.
 PR 05-JAN-2001; 2001US-0259678.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Barash SC, Ruben SM;
 XX WPI; 2001-465460/50.
 DR N-PDB; AAS27325.
 XX
 PT Novel polypeptides useful for diagnosing, treating, preventing and/or
 PT prognosing disorders related to the proteins, including cancers, immune
 PT disorders and neuronal disorders
 XX
 PS Claim 1; SEQ ID No 973; 880pp; English.
 XX
 CC The invention relates to novel isolated polypeptides (I), and
 CC polynucleotides (II). (I), (II) and the antibody to (I) are useful for
 CC diagnosing, preventing and treating diseases including immune system
 CC disorders (e.g. congenital and acquired immunodeficiencies, autoimmune
 CC disorders (e.g. rheumatoid arthritis), inflammatory conditions, organ
 CC transplant rejections and graft versus host disease, infectious diseases
 CC (e.g. hepatitis C), bleeding disorders, haemoglobin abnormalities and
 CC other blood-related disorders (sickle cell anaemia), myeloproliferative
 CC disorders, primary haematopoietic disorders, hyperproliferative
 CC disorders (e.g. Gaucher's disease and cancer), neurodegenerative
 CC disorders (e.g. Alzheimer's disease, Parkinson's disease), chromosomal
 CC abnormalities (Down syndrome), ischaemic injury (e.g. stroke), renal
 CC disorders (e.g. glomerulonephritis), cardiovascular disorders, in
 CC (e.g. arrhythmia), respiratory disorders, dermatological disorders, in
 CC wound healing, epithelial cell proliferation, endocrine disorders (e.g.
 CC Addison's disease), reproductive system disorders, gastrointestinal
 CC disorder (inflammatory disorders), liver disorders (cirrhosis),
 CC as stimulators of B-cell responsiveness to pathogens, activators of
 CC T-cells, to induce higher affinity antibodies, and as a means to induce
 CC tumour proliferation in pathologies e.g. acquired immune deficiency
 CC syndrome (AIDS). AAU17059-AAU17683 represent novel signal transduction
 CC pathway protein, amino acid sequences of the invention.
 XX
 Query Match 38.3%; Score 240; DB 22; Length 407;
 Best Local Similarity 100.0%; Pred. No. 7.5e-17;
 Matches 49; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 70 VKANLSEVLVSSVLYGNVTSTVEYGAFTCSIONISFSSFTIQRAQPTSH 118
 DB 67 VKANLSEVLVSSVLYGNVTSTVEYGAFTCSIONISFSSFTIQRAQPTSH 115
 RESULT 5
 ID AAM43652
 ID AAM43652 standard; Protein; 407 AA.
 AC AAM43652;
 XX
 DT 22-OCT-2001 (first entry)
 XX
 XX Human polypeptide SEQ ID NO 330.
 DE
 XX Human; antiarrhythmic; antirheumatic; antiproliferative; vasotropic;
 KW cerebroprotective; nootropic; neuroprotective; antibacterial; vituocic;
 KW fungicide; ophthalmological; cytostatic; immunosuppressive; nootropic;
 KW neuroprotective; antiarrhythmic; hepatotropic; antidiabetic;
 KW antiinflammatory; anticancer; vulnery; anticonvulsant; antibacterial;
 KW antiparasitic; gardiant; gene therapy; cancer; immune disorder;
 KW cardiovascular disorder; neurological disease; infection; human.
 OS Homo sapiens.
 XX
 XX
 PN WO200155308-A2.
 XX

PD 02-AUG-2001.
XX 17-JAN-2001; 2001WO-US01309.
PF
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209457.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 11-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 14-JUL-2000; 2000US-0217496.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220966.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225759.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226686.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232396.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.

PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241826.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0244674.
PR 08-NOV-2000; 2000US-0244675.
PR 08-NOV-2000; 2000US-0244676.
PR 08-NOV-2000; 2000US-0244677.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251889.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
(HUMA-) HUMAN GENOME SCI INC.
Rosen CA, Barash SC, Ruben SM;
WPI; 2001-488781/53.

PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250161.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251038.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
PA (HUMA-) HUMAN GENOME SCI INC.
XX
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
XX WPI: 2001-488781/53.
DR N-PSDB; AAI63889.
XX
XX
PT New isolated nucleic acids and polypeptides, useful for diagnosing,
PT treating and/or preventing human diseases and disorders -
XX
XX
XX Claim 11: SEQ ID NO 261; 664pp + sequence listing; English.
XX
XX The invention relates to human polynucleotides (AAI63803-AAI64012) and
CC or ameliorating medical conditions e.g. by protein or gene therapy. The
CC genes were isolated from a range of human tissues disclosed in the
CC specification. The nucleic acids, proteins, antibodies and (ant)agonists
CC are useful in the diagnosis, treatment and prevention of: (a) cancer,
CC e.g. breast and ovarian cancer and other cancers of the adrenal gland,

CC bone, bone marrow, breast, gastrointestinal tract, liver, lung, or
CC uterine; (b) immune disorders e.g. Addison's disease, allergies,
CC autoimmune haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus,
CC Crohn's disease, multiple sclerosis, rheumatoid arthritis and ulcerative
CC colitis; (c) cardiovascular disorders such as myocardial ischaemias;
CC (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
CC epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
CC and parasitic infections.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pcl_sequences.
XX
XX
SQ Sequence 410 AA:
Query Match 38.3%; Score 240; DB 22; Length 410;
Best Local Similarity 100.0%; Pred. No. 7.6e-17;
Matches 49; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 70 VKANLSEVLVSSVLGVNVTSTVEYGAFTCSIONISPSFTLRAGPTSH 118
Db 70 VKANLSEVLVSSVLGVNVTSTVEYGAFTCSIONISPSFTLRAGPTSH 118
RESULT 7
AAI638416
ID AAI638416 standard; Protein; 363 AA.
XX
AC AAI638416;
XX
DT 14-MAR-2001 (first entry)
XX
DE Lung cancer associated polypeptide sequence SEQ ID 754.
XX
XX Homo sapiens.
OS
XX WO20005180-A2.
PN
XX 21-SEP-2000.
PD
XX 08-MAR-2000; 2000WO-US05918.
XX
XX 12-MAR-1999; 99US-0124270.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA (ROSE/) ROSEN C A.
XX
XX Ruben SM;
PI
XX
XX WPI: 2000-587514/55.
DR N-PSDB; AAI6292.
XX
XX Lung cancer associated gene sequences, referred to as lung cancer
PT antigens, useful for treatment, prevention, and diagnosis of disorders
PT such as lung cancer -
XX
XX
XX Claim 11: Page 1271-1272; 1425pp; English.
XX
XX Polynucleotide sequences AAI7982 - AAI7984 encode human lung cancer
CC associated proteins represented in AAI58106 - AAI58148. Lung cancer
CC associated proteins and polynucleotide sequences, their agonists, and
CC antagonists may have neuroprotective, cytoprotective, cardioprotective;
CC immunomodulatory; muscular active general; vulnerrary; gastrointestinal
CC general; nephrotropic; antiinfective; gynecological; or antibacterial
CC activity. The invention also includes antibodies specific for the
CC protein or polynucleotide sequences. The lung cancer associated
CC polynucleotide sequences may be used for detection of lung cancer,
CC chromosome identification, as chromosome markers, and for numerous other

CC diagnostic or research purposes. The proteins may be used to treat
 CC disorders such as neural, immune, muscular, reproductive,
 CC gastrointestinal, pulmonary, cardiovascular, renal, and proliferative
 CC disorders. The proteins may also be used in the treatment of wounds and
 CC infectious diseases. Polynucleotide sequences AAF18425 - AAF18433 and
 CC AAB30570 are used in the course of the invention for the
 CC identification and characterization of the polynucleotide and protein
 CC sequences.

*SQ Sequence 363 AA:

Query Match 37.4%; Score 234; DB 21; Length 363;
 Best Local Similarity 98.0%; Pred. No. 2.8e-16;
 Matches 48; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 70 VKANLSEVLYSVLVGVNVTSTEVYGAFTCSIONISFSSFTLQRAQPTSH 118
 Db 23 VKANLSEVLYSVLVGVNVTSTEVYGAFTCSIONISFSSFTLQRAQPTSH 71

RESULT 8

00570 AAB30570 standard; Protein: 871 AA.

XX AAB30570;

DT 19-MAR-2001 (first entry)

DE A splice variant of a signal transduction polypeptide.

KW Signal transduction; H19G5; kinase; cardiac disease; angina pectoris;
 KW congestive heart failure; dilated congestive cardiomyopathy;
 KW hypertrophic cardiomyopathy; restrictive cardiomyopathy; hypertension;
 KW mitral valve disease; aortic valve disease; tricuspid valve disease;
 KW myocardial infarction; cardiac arrhythmia; arteriosclerosis;
 KW atherosclerosis; cardiac tumour; microbial infection; splice variant.

OS Homo sapiens.

XX WO200063381-A1.

PD 26-OCT-2000.

PF 11-APR-2000; 2000WO-US09488.

PR 16-APR-1999; 99US-0129553.

PA (SCIO-) SCIOS INC.

XX Zeng W, Stanton L, Kong H;

XX WPI; 2001-007013/01.

Claim 1; Page 74-76; 81pp; English.

CC The present sequence represents a splice variant of human in signal
 CC transduction polypeptide. The polypeptide is designated H19G5. The
 CC protein is capable of regulating signal transduction and exhibits kinase
 CC activity. The H19G5 transcript is expressed in the heart. H19G5
 CC polypeptides and polynucleotides are useful for preventing or treating a
 CC cardiac disease, such as congestive heart failure, dilated congestive
 CC cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy,
 CC mitral valve disease, aortic valve disease or tricuspid valve disease,
 CC angina pectoris, myocardial infarction, cardiac arrhythmia, pulmonary,
 CC arterial or thrombovascular hypertension, arteriosclerosis, atherosclerosis,
 CC and cardiac tumours in humans. The polypeptide is also useful for
 CC detecting the expression of a protein capable of regulating signal
 CC transduction or the expression of a protein capable of acting as a donor
 CC or acceptor molecule of a phosphate group. The monoclonal antibodies can

CC be used as probes for detecting discrete antigens expressed by tissue or
 CC cell samples, and therefore used in humans for localization and
 CC monitoring of microbial infection.

*SQ Sequence 871 AA:

Query Match 16.8%; Score 105; DB 22; Length 871;
 Best Local Similarity 31.4%; Pred. No. 0.034;
 Matches 33; Conservative 11; Mismatches 29; Indels 32; Gaps 5;
 Oy 6 DRAPFLSPEDVLPALGSSVALNCTAWVSGPCHSPSVQ-WKDDLPGLGHS 63
 Db 363 DRAPFLRELSEDEV-VLGOSVTLACV-----SAQPAQATWSKDGAPL----- 406
 Oy 64 LHEYSWVKNLSEVLYVS-----VLGVNVTSTEVYGAFTCSION 102
 Db 407 -----ESSSRVLTSLATLKNFQLTLVVAEDLVITCSVN 443

RESULT 9

AAE16274 AAE16274 standard; Protein: 871 AA.

XX AAE16274;

DT 26-MAR-2002 (first entry)

DE Human kinase PKIN-20 protein.

KW Human; kinase; PKIN-20; cancer; leukemia; adenocarcinoma; osteoporosis;
 KW immune disorder; atherosclerosis; Crohn's disease; Hodgkin's disease;
 KW Acquired Immune Deficiency Syndrome; AIDS; Addison's disease; anaemia;
 KW allergy; asthma; adult respiratory distress syndrome; multiple sclerosis;
 KW autoimmune thyroiditis; bronchitis; diabetes mellitus; osteoarthritis;
 KW Good pasture's syndrome; Graves' disease; pancreatitis; psoriasis;
 KW rheumatoid arthritis; ulcerative colitis; cirrhosis; Cushing's syndrome;
 KW hepatitis; hypothyroidism; cerebral palsy; cataract; angina pectoris;
 KW cardiovascular disease; hypertension; vascular disease; myocarditis; obesity;
 KW congestive heart failure; ischaemic heart disease; lung tumour; gout;
 KW fatty liver; Niemann-Pick's disease; gene therapy.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Domain 575..827 /note="Eukaryotic protein kinase domain"

FT Domain 580..812 /label="Protein_kinase_domain"

PN WO200196547-A2.

PD 20-DEC-2001.

PF 14-JUN-2001; 2001WO-US19444.

PR 15-JUN-2000; 2000US-212073P.

PR 23-JUN-2000; 2000US-213467P.

PR 30-JUN-2000; 2000US-213651P.

PR 07-JUL-2000; 2000US-216605P.

PR 13-JUL-2000; 2000US-218372P.

PR 25-AUG-2000; 2000US-228056P.

XX (INCY-) INCYTE GENOMICS INC.

XX Yue H, Lal P, Bandman O, Borowsky ML, Au-Young J, Lu Y;

PI Gandhi AR, T-ibbles CA, Walla NK, Yao MG, Lu DM, Greenwald SR;

PI Ramkumar J, Griffin JA, Kearney L, Burford N, Nguyen DB, Tang YF;

PI Baughn MR, He A, Thornton M, Hailia A, Patterson C, Gururajan R;

PI Lo TP, Khan F, Reclupon SA, Azimzai Y, Policky JL, Ding L;

PI Grether M, Elliott VS, Thangavelu K, Batra S, Ison CH;

XX WPI; 2002-090207/12.

DR N-PSDB; AAD26467.

XX New polypeptides, useful for diagnosing, treating or preventing
PT disorders of growth and development, cardiovascular and lipid, and
PT diseases such as cancer, comprise human kinase polypeptides -
PS Claim 1; Page 164-165; 197pp; English.

XX The invention relates to human kinase PKIN proteins and their
CC corresponding cDNAs. A composition containing PKIN agonist is useful for
CC treating a disease or condition associated with decreased expression of
CC PKIN and a composition comprising PKIN antagonist is useful for treating
CC a disease or condition associated with overexpression of PKIN. The
CC disorders include cancer (leukemia, adenocarcinoma, lymphoma, melanoma,
CC myeloma, sarcoma, teratocarcinoma, Hodgkin's disease); immune disorder
CC (Acquired Immune Deficiency Syndrome (AIDS), asthma, Addison's disease,
CC atherosclerosis, anemia, allergies, adult respiratory distress syndrome,
CC autoimmune thyroiditis, gout, bronchitis, Crohn's disease, diabetes
CC mellitus, multiple sclerosis, good pasture's syndrome, Graves' disease,
CC osteoarthritis, osteoporosis, pancreatitis, psoriasis, Reiter's syndrome,
CC rheumatoid arthritis, Sjogren's syndrome, uveitis, ulcerative colitis,
CC bacterial, parasitic, fungal, viral, protozoal and helminthic infections)
CC growth and development disorders (arteriosclerosis, cataracts); Cardio
CC Cushing's syndrome, hypothyroidism, cerebral palsy, cataracts); Cardio
CC vascular disease (arteriovenous fistula, hypertension, vasculitis,
CC aneurysms, congestive heart failure, angina pectoris, myocarditis,
CC ischaemic heart disease, chronic bronchitis, lung tumours); lipid
CC disorder (fatty liver, Fabry's disease, Niemann-Pick's disease,
CC hypcholesterolaemia, obesity). PKIN DNA is useful for assessing
CC toxicity of a test compound and in gene therapy. The present sequence
CC is human PKIN-20 protein.

XX SQ Sequence 871 AA;

Query Match 16.8%; Score 105; DB 23; Length 871;
Best Local Similarity 31.4%; Pred. No. 0.034;
Matches 33; Conservative 11; Mismatches 29; Indels 32; Gaps 5;

QY 6 DRAPDLFSEDDOVLRLPALGSSVALNCTAMVWSGPHCSLPVSQ--WLKDLPLGIGGHS 63
DB 363 DRAPFLRLSLDETV--VLGQSVTLACQV-----SAQPAQATWSKQDAPL----- 406

QY 64 LHEYSWVKANLSEVLVS-----VLGVNVTSTEVYGAFTCSION 102
DB 407 -----ESSSRVLISATLKNQQLTLVVAEDGVYTCVSN 443

RESULT 10
ID AAB30567

XX AAB30567 standard; Protein: 1351 AA.

XX AAB30567;

DT 19-MAR-2001 (first entry)

XX Amino acid sequence of a human signal transduction polypeptide.

XX Signal transduction; H19G5; kinase; cardiac disease; angina pectoris;
XX congestive heart failure; dilated congestive cardiomyopathy;
XX hypertrophic cardiomyopathy; restrictive cardiomyopathy; hypertension;
XX mitral valve disease; aortic valve disease; tricuspid valve disease;
XX myocardial infarction; cardiac arrhythmia; arteriosclerosis;
XX atherosclerosis; cardiac tumour; microbial infection.

OS Homo sapiens.

PN WO200063381-A1.

PD 26-OCT-2000.

PF 11-APR-2000; 2000WO-US09488.

PR 16-APR-1999; 99US-0129553.

XX

PA (SCIO-) SCIOS INC.

PI Zeng W, Stanton L, Kong H;

DR WPI: 2001-007013/01.

DR N-PSDB: AAC62285.

PT Novel h19G5 polypeptides capable of regulating signal transduction and
PT exhibiting kinase activity useful for identifying antibodies to treat
PT cardiac diseases, and additional mediators of signal transduction -
PS Claim 1; Page 55-57; 81pp; English.

XX The present sequence represents a human protein with putative function
CC in signal transduction. The polypeptide is designated H19G5. The protein
CC is capable of regulating signal transduction and exhibits kinase
CC activity. The H19G5 transcript is expressed in the heart. H19G5
CC polypeptides and polynucleotides are useful for preventing or treating a
CC cardiac disease, such as congestive heart failure, dilated congestive
CC cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy,
CC mitral valve disease, aortic valve disease or tricuspid valve disease,
CC angina pectoris, myocardial infarction, cardiac arrhythmia, pulmonary,
CC arterial or renovascular hypertension, arteriosclerosis, atherosclerosis
CC and cardiac tumours in humans. The polypeptide is also useful for
CC detecting the expression of a protein capable of regulating signal
CC transduction or the expression of a protein capable of acting as a donor
CC or acceptor molecule of a phosphate group. The monoclonal antibodies can
CC be used as probes for detecting discrete antigens expressed by tissue or
CC cell samples, and therefore used in humans for localization and
CC monitoring of microbial infection.

XX SQ Sequence 1351 AA;

Query Match 16.8%; Score 105; DB 22; Length 1351;
Best Local Similarity 31.4%; Pred. No. 0.06;
Matches 33; Conservative 11; Mismatches 29; Indels 32; Gaps 5;

QY 6 DRAPDLFSEDDOVLRLPALGSSVALNCTAMVWSGPHCSLPVSQ--WLKDLPLGIGGHS 63
DB 843 DRAPFLRLSLDETV--VLGQSVTLACQV-----SAQPAQATWSKQDAPL----- 886

QY 64 LHEYSWVKANLSEVLVS-----VLGVNVTSTEVYGAFTCSION 102
DB 887 -----ESSSRVLISATLKNQQLTLVVAEDGVYTCVSN 923

RESULT 11
ID AAB30568

XX AAB30568 standard; Protein: 1610 AA.

XX AAB30568;

DT 19-MAR-2001 (first entry)

XX A full length human signal transduction polypeptide.

XX Signal transduction; H19G5; kinase; cardiac disease; angina pectoris;
XX congestive heart failure; dilated congestive cardiomyopathy;
XX hypertrophic cardiomyopathy; restrictive cardiomyopathy; hypertension;
XX mitral valve disease; aortic valve disease; tricuspid valve disease;
XX myocardial infarction; cardiac arrhythmia; arteriosclerosis;
XX atherosclerosis; cardiac tumour; microbial infection.

OS Homo sapiens.

PN WO200063381-A1.

PD 26-OCT-2000.

PF 11-APR-2000; 2000WO-US09488.

PR 16-APR-1999; 99US-0129553.

XX

PA (SCIO-) SCIOS INC.
 XX Zeng W, Stanton L, Kong H;
 PI WPI: 2001-007013/01.
 DR N-PSDB; AAC62286.
 XX Novel h19c5 polypeptides capable of regulating signal transduction and
 PT exhibiting kinase activity useful for identifying antibodies to treat
 PR cardiac diseases, and additional mediators of signal transduction
 PS Claim 1: Page 61-65; 81pp; English.

CC The present sequence represents a human protein with putative function
 CC in signal transduction. The polypeptide is designated h19c5. The protein
 CC is capable of regulating signal transduction and exhibits kinase
 CC activity. The h19c5 sequence is expressed in the heart. h19c5
 CC polypeptides and polynucleotides are useful for preventing or treating a
 CC cardiac disease, such as congestive heart failure, dilated congestive
 CC cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy,
 CC mitral valve disease, aortic valve disease or tricuspid valve disease,
 CC arterial or rheumatic heart disease, cardiac arrhythmia, pulmonary,
 CC and cardiac tumors in humans. The polypeptide is also useful for
 CC detecting the expression of a protein capable of regulating signal
 CC transduction or the expression of a protein capable of acting as a donor
 CC or acceptor molecule of a phosphate group. The monoclonal antibodies can
 CC be used as probes for detecting discrete antigens expressed by tissue or
 CC cell samples, and therefore used in humans for localization and
 CC monitoring of microbial infection.

XX Sequence 1610 AA:
 SQ
 Query Match 16.8%; Score 105; DB 22; Length 1610;
 Best Local Similarity 31.4%; Pred. NO. 0.075; 29; Indels 32; Gaps 5;
 Matches 33; Conservative 11; Mismatches 29; Indels 32; Gaps 5;

QY 6 DRAPFLSPEDVLRPAGSSVALNCTAMVYSGPHCSLPVQ--WLKDGILPGIGHY 63
 DB 1102 DRAPFLRELSDERY--VLGOSVTLACV-----SAQPAQAQWMSKDGAPL----- 1145
 QY 64 LHEYSWKANLSEVLYSS-----VLGVNVTSTFVYGAFTGSION 102
 DB 1146 -----ESSSRVLISATLKNFOLLTLIVVAEDLVYTCVS 1182

RESULT 12
 AAB85504
 ID AAB85504 standard; protein; 1618 AA.

XX AAB85504;
 DT 25-SEP-2001 (first entry)
 DE Human protein kinase SGK145.
 XX
 KW Protein kinase; enzyme; cytosolic; neurotrophic; neuroprotective; human;
 KW antiparkinsonian; virucide; antibacterial; antifungal; antimigraine;
 KW analgesic; hypotensive; hypertensive; immunosuppressive; anti-allergic;
 KW antiproliferative; antitumor; antidiabetic; antihypertensive; anorectic;
 KW osteoporotic; thrombolytic; antiarteriosclerotic; antidiabetic; gene therapy.
 XX Homo sapiens.
 OS
 XX MO20015356-A2.
 XX 02-AUG-2001.
 XX 25-JAN-2001; 2001WO-US02337.
 XX 25-JAN-2000; 2000US-0178078.
 PR 31-JAN-2000; 2000US-0179364.

PR 17-FEB-2000; 2000US-0183173.
 PR 17-MAR-2000; 2000US-0190162.
 PR 29-MAR-2000; 2000US-0193404.
 PR 13-NOV-2000; 2000US-0247013.
 XX
 XX (SUGEN-) SUGEN INC.
 XX Plowman G, Whyte D, Manning G, Sudarsanam S, Martinez R;
 PI WPI: 2001-476202/51.
 DR N-PSDB; AAH46904.
 XX Kinase polypeptides useful for treating cancers, Alzheimer's disease,
 PT viral infections, diabetes, obesity, organ transplant rejection and
 PR rheumatoid arthritis.
 PS Claim 7: Page 215; 218pp; English.

CC The invention provides human protein kinases and protein kinase-like
 CC enzymes and polynucleotides encoding the polypeptides. The kinase
 CC polypeptides and their modulators are useful for treating a disease or
 CC disorder such as cancer, immune-related diseases, cardiovascular disease,
 CC brain or neuronal-associated disease and metabolic disorders, including
 CC cancers of tissues, cancers of hematopoietic origin, diseases of the
 CC central nervous system, diseases of the peripheral nervous system,
 CC Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic
 CC lateral sclerosis, viral infections, infections caused by prions,
 CC mood and lung, ocular diseases, migraines, pain, sexual dysfunction,
 CC hypothyroidism, attention disorders, neurological disorders, hypokinesias,
 CC hyperthyroidism, psychiatric disorders, cognitive disorders, dyslexias,
 CC osteoarthritis, arthritis, autoimmunity, atherosclerosis, psoriasis,
 CC for treating diabetes, chronic inflammatory diseases, chronic
 CC inflammatory bowel disease, rheumatoid arthritis, metabolic disorders
 CC such as diabetes, obesity, cardiovascular diseases such as reperfusion
 CC injury, coronary thrombosis, clotting disorders and atherosclerosis,
 CC ocular diseases such as glaucoma, retinopathy and macular degeneration,
 CC psychiatric and neurological disorders such as anxiety, schizophrenia,
 CC dementia, manic depression, etc. The polynucleotides are useful in gene
 CC therapy techniques to treat the above mentioned disorders. Sequences
 CC AAB85491-85522 represent the human protein kinases of the invention.

XX Sequence 1618 AA:
 SQ
 Query Match 16.8%; Score 105; DB 22; Length 1618;
 Best Local Similarity 31.4%; Pred. NO. 0.075; 29; Indels 32; Gaps 5;
 Matches 33; Conservative 11; Mismatches 29; Indels 32; Gaps 5;

QY 6 DRAPFLSPEDVLRPAGSSVALNCTAMVYSGPHCSLPVQ--WLKDGILPGIGHY 63
 DB 1110 DRAPFLRELSDERY--VLGOSVTLACV-----SAQPAQAQWMSKDGAPL----- 1153
 QY 64 LHEYSWKANLSEVLYSS-----VLGVNVTSTFVYGAFTGSION 102
 DB 1154 -----ESSSRVLISATLKNFOLLTLIVVAEDLVYTCVS 1190

RESULT 13
 AAE24151
 ID AAE24151 standard; protein; 1665 AA.

XX AAE24151;
 DT 23-SEP-2002 (first entry)
 DE Human kinase (PKIN)-22 protein.
 XX
 KW Human; kinase; PKIN; cancer; immune system disorder; atherosclerosis;
 KW acquired immune deficiency syndrome; AIDS; Addison's disease; allergy;
 KW asthma; multiple sclerosis; psoriasis; arteriosclerosis; cirrhosis;
 KW development; hepatitis; cardiovascular; hypertension; drug screening;
 KW myocardial infarction; Goodpasture's syndrome; lipid disorder; growth;
 KW fatty liver; Gaucher's disease; Niemann-Pick's disease; anorectic;

KW hypercholesterolaemia; obesity; gene therapy; cytostatic; anti-HIV;
 KW neuroprotective; hepatotropic; hypotensive; cardiast; nephrotropic;
 KW hyperlipidaemia; enzyme.
 OS Homo sapiens.
 Key Location/Qualifiers
 FH 68..128
 FT Domain /note="Immunoglobulin domain"
 FT 165..418
 FT Domain /note="Eukaryotic protein kinase domain"
 FT 167..401
 FT Domain /note="Protein kinase domain"
 FT 1174..1235
 FT Domain /note="Immunoglobulin domain"
 FT 1369..1621
 FT Domain /note="Eukaryotic protein kinase domain"
 FT 1372..1606
 FT Domain /note="Protein kinase domain"
 PN MO200233099-A2.
 PD 25-APR-2002.
 XX 20-OCT-2001; 2001WO-US47728.
 XX 20-OCT-2000; 2000US-242410P.
 PR 27-OCT-2000; 2000US-244068P.
 PR 03-NOV-2000; 2000US-245708P.
 PR 09-NOV-2000; 2000US-247672P.
 PR 16-NOV-2000; 2000US-249565P.
 PR 22-NOV-2000; 2000US-252730P.
 PR 01-DEC-2000; 2000US-250607P.
 XX (INCY-) INCYTE GENOMICS INC.
 XX Gururajan R, Baughn MR, Walla NK, Elliott VS, Xu Y, Arvizu C;
 PI Yao MG, Rankumar J, Ding L, Tang YT, Hafeilia AZA, Nguyen DB;
 PI Ganhi AR, Lu Y, Yue H, Burford N, Bandman O, Tribouley CM;
 PI Lal PG, Recipon SA, Lu DM, Borowsky ML, Thornton M, Swarnaker A;
 PI Thangavelu K, Khan FA, Ison CH;
 XX MPI: 2002-454603/48.
 DR N-PSDB: AAD38865.
 XX New human kinase polypeptide, for diagnosing, preventing and treating
 cancer, immune system disorders, growth and development disorders,
 cardiovascular disorders and lipid disorders
 PS Claim 1: Page 182-186; 210pp; English.
 XX The invention relates human kinases (PKIN) and their corresponding
 CC nucleic acid sequences. PKIN and its DNA are useful for diagnosing,
 CC treating and preventing cancer, an immune system disorder (e.g.,
 CC acquired immune deficiency syndrome (AIDS), Addison's disease, allergy,
 CC asthma, atherosclerosis, multiple sclerosis, psoriasis), disorders
 CC affecting growth and development (e.g., arteriosclerosis, cirrhosis,
 CC hepatitis), cardiovascular disorder (e.g., hypertension, myocardial
 CC infarction, Goodpasture's syndrome), and a lipid disorder (e.g., fatty
 CC liver, Gaucher's disease, Niemann-Pick's disease, hypercholesterolaemia,
 CC hyperlipidaemia, obesity), and for assessing the effects of exogenous
 CC compounds. Anti-PKIN antibody is useful in a diagnostic test for a
 CC condition or a disease associated with the expression of PKIN in a
 CC biological sample. A composition comprising PKIN or an agonist or
 CC antagonist of PKIN is useful for treating a disease or condition
 CC associated with decreased or increased expression of functional PKIN.
 CC PKIN is useful in a number of drug screening techniques and to analyze
 CC the proteome of a tissue or cell type. PKIN DNA is useful for creating
 CC knockin humanised animals or transgenic animals to model human diseases,
 CC and in somatic or germline gene therapy. The present sequence is human
 CC PKIN protein.
 XX Sequence 1665 AA;
 SQ

Query Match 16.8%; Score 105; DB 23; Length 1665;
 Best Local Similarity 31.4%; Pred. No. 0.078;
 Matches 33; Conservative 11; Mismatches 29; Indels 32; Gaps 5;
 QY 6 DRAPDFLSPSEDDVLRPALGSSVALNCTAWVSGPHCSLPSVQ--WLKDGFLPGIGGHS 63
 DB 1157 DRAPFTLRELSDFTV--VLGGSVTLACQV-----SAQPAAGATWSKDGAPL----- 1200
 QY 64 LHEYSWKANLSEVLVS-----VLGVNVTSTEVYGAFTCSIQN 102
 DB 1201 -----ESSSRVLISATLKNFQLTLTVVVAEDIGVYTCGSVN 1237
 RESULT 14
 AAO15372
 ID AAO15372 standard; Protein; 1665 AA.
 XX AAO15372;
 AC AAO15372;
 XX 19-SEP-2002 (first entry)
 DT Human myosin light chain kinase subfamily-related kinase protein.
 XX Human: gene therapy; chromosome 1; kinase protein;
 KW myosin light chain kinase subfamily; kinase protein-mediated disease;
 KW transgenic animal.
 XX Homo sapiens.
 OS MO200240683-A2.
 PN 23-MAY-2002.
 PD 22-OCT-2001; 2001WO-US32616.
 XX 14-NOV-2000; 2000US-0711134.
 PR 17-MAY-2001; 2001US-0856664.
 XX (PEKE) PE CORP NY.
 XX Wei M, Ketchum K, Di Francesco V, Beasley EM;
 PI MPI: 2002-500223/53.
 DR N-PSDB: AAL43908, AAL43909.
 XX New kinase proteins related to myosin light chain kinase subfamily and
 encoding polynucleotide, useful for diagnosing, treating disease or
 condition mediated by the kinase protein and for identifying modulators
 PS Claim 1: Fig 2; 96pp; English.
 XX The invention comprises the amino acid and coding sequences (located on
 CC chromosome 1) of a human kinase protein that is related to the myosin
 CC light chain kinase subfamily. The human kinase DNA and protein sequences
 CC of the invention are useful for identifying agents that modulate the
 CC activity of the human kinase protein. Kinase-modulating agents are useful
 CC for treating a disease or condition mediated by a human kinase protein.
 CC The human kinase DNA sequences can be used to produce transgenic animals
 CC which are useful for studying the function of kinase proteins and
 CC identifying/evaluating modulators of kinase protein activity. The present
 CC amino acid sequence represents the human kinase protein of the invention.
 XX Sequence 1665 AA;
 SQ
 Query Match 16.8%; Score 105; DB 23; Length 1665;
 Best Local Similarity 31.4%; Pred. No. 0.078;
 Matches 33; Conservative 11; Mismatches 29; Indels 32; Gaps 5;
 QY 6 DRAPDFLSPSEDDVLRPALGSSVALNCTAWVSGPHCSLPSVQ--WLKDGFLPGIGGHS 63
 DB 1157 DRAPFTLRELSDFTV--VLGGSVTLACQV-----SAQPAAGATWSKDGAPL----- 1200

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd

OM protein - protein search, using sw model

Run on: November 14, 2002, 17:29:38 ; Search time 17 Seconds
(without alignments)
667.286 Million cell updates/sec

Title: US-09-598-443-2_COPY_1_118

Sequence: 1 MPGVCDRAPDFLSPSEDVL.....SIQNISFSSFTLQKAGPTSH 118

Scoring table: BLOSUM62

283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

```
Minimum DB seq length: 0
Maximum DB seq length: 20000000000
```

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : PIR_73:*

```
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

SUMMARIES

Query No.	Score	Match	Length	DB	ID	Description
1	93.5	14.9	7962	2	I38346	elastic titin - hu
2	91.5	14.6	1323	2	PN0568	connectin 3B - chn
3	90	14.4	6831	2	A88852	protein unc-22 (lm
4	90	14.4	6839	2	S57242	twitchin [similar
5	90	14.4	7160	2	T27935	hypothetical prot
6	87.5	14.0	5175	2	T20992	hypothetical prot
7	87.5	14.0	5198	2	T43290	hemolentin precu
8	83.5	13.3	244	2	AE3502	amiodontiferase t
9	83.5	13.3	1694	2	S50065	sialoadhesin - mov
10	82	13.1	588	2	I37202	B-CAM protein - hu
11	82	13.1	628	2	I38000	Lutheran blood gro
12	81.5	13.0	650	1	JC1450	fibroblast growth
13	81	12.9	238	2	A49633	Ig lambda-like cha
14	80.5	12.9	799	2	S18209	fibroblast growth
15	80.5	12.9	6805	2	S20951	titin - rabbit (f
16	80	12.8	1896	2	T08851	Down syndrome cell
17	80	12.8	6642	2	T29757	protein UNC-89 - C
18	80	12.8	26926	1	I38344	titin, cardiac mus
19	78.5	12.5	483	2	T17346	hypothetical prot
20	77.8	12.5	2783	2	T34416	hypothetical prot
21	77.5	12.4	361	2	PN0020	fibroblast growth
22	77.5	12.4	822	1	TVMSFG	fibroblast growth
23	77.5	12.4	832	2	JH0393	fibroblast growth
24	77.5	12.4	1091	2	AS8532	glial cell membr
25	77	12.3	733	2	T49293	fibroblast growth
26	77	12.3	822	2	I49289	fibroblast growth
27	77	12.3	889	2	E87304	Tonb-dependent re
28	77	12.3	1240	2	T03097	CDO protein - hu
29	76.5	12.2	1142	2	S36845	myosin-binding pr

30	76.5	12.2	124.1	2	T37190	nephlin - human
31	76	12.1	602	2	A35564	prostaglandin-endo
32	75.5	12.1	662	2	C40862	heparin-binding gr
33	A56795	12.1	799	2	A56795	fibroblast growth
34	75.5	12.1	822	1	TVMHFG	fibroblast growth
35	75	12.0	276	2	S75249	esterase s110992 -
36	75	12.0	460	2	A56182	fibroblast growth
37	75	12.0	840	2	S24108	protein-tyrosine k
38	74.5	11.9	802	1	TVMHFG	fibroblast growth
39	74.5	11.9	819	1	TVMHFG	fibroblast growth
40	74	11.8	162	2	I51668	tumor suppressor -
41	73.5	11.7	602	2	S39782	cyclooxygenase 1 -
42	73.5	11.7	1021	2	T42634	connectin/citin -
43	73.5	11.7	1666	2	A48594	skelemin - mouse
44	73	11.7	750	2	S41051	fibroblast growth
45	73	11.7	1272	2	S26180	neurofascin - chla

ALIGNMENTS

RESULT

elastic titin - human (fragment)

C;Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 21-Jul-2000

R;Labeit, S.; Kolme

A;Title: Titins: giant pro

A;Accession: I38346

A;Molecule type: mRNA

A: Cross-references: EMBL:X90569; NID:g1017426; PIDN:CAA62189.1; PID:g1017427

A;Gene: GDB:TTN

A:Map position: 2q31-2q31

Query Match

Matches 38; Conservative 7; Mismatches 32; Indels 39; Gaps 7;

10 DFLSPSEDQVLR-----PALGSSVALNCTAWVSGPHCSLP-SVQWL 50

Db 1883 DFGSSCDAYLRVLDQNI PPSFTKLT KMDKVLGSSIHMECK--VSG--SLPISAQWF 1936

51 KDGLPLGIGHSL--HEYSWKANLSEVLVSSVLGVNTSTEVYGAFTCSIONIS 104

Db 1937 KDGKEISTSAKYRLVCHERS-----VS--LEVNNELEDTANYTCKVSNA 1980

RESULT 2

connectin 3B - chicken (fragment)

C;Species: Gallus gallus (chicken)

C:Accession: PN0568

Biochem. Biophys. Res. Commun. 194, 1288-1291, 1993

A; Reference number: PN0568; MUID:93356802; PMID:8352787

A;Molecule type: mRNA

A; Cross-references: DDBJ: D16541; NID: g391629; PID: d1004495; PID: g391630

C;Comment: This protein string-like single molecule spans from the 2 line to the M 11

Query Match 14.68; Score 91.5; DB 2; Length 1323;

Best Local Similarity 24.5%; Pred. No. 0.83;
Matches 27; Conservative 21; Mismatches 31; Indels 31; Gaps 5;

Qy 19 VLRLPAL-----GSSVALNCTAMVYSGPHCLSPV--QWLKDGPLGIGHYSLH 65
Db 959 VLEPVERHLHDTTFKBSNTTTLSC-----QFSTPNKSKQWYRNKRPRIKIGKRY-- 1008
Qy 66 EYSWKANLSEVLVSVLVGVNTSTEVYGAFTCSIGNISFSPTLQKAPG 115
Db 1009 --TSVSDKRVHKLITKDV-----RTEDGGYCTKLDLLETTADLTIEAEP 1050

RESULT 3
A:Accession: A88852
A:Title: protein unc-22 [imported] - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C>Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 24-May-2001
C:Accession: A88852
R:Anonymous; the C. elegans Sequencing Consortium.
S:Science 282, 2012-2018, 1998
File: Genome sequence of the nematode C. elegans: a platform for investigating biology
Note: see web sites genome.wustl.edu/gsc/C.elegans/ and www.sanger.ac.uk/Projects/C.ele
A:Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103, 1999; and
A:Accession: A88852
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-6831 <STOS>
A:Cross-references: GB:chr_IV; PIDN:CA98081.1; PID:93881830; GSPDB:GN00022
C:Genetics:
A:Gene: unc-22
A:Map position: 4
C:Superfamily: twitchin; fibronectin type III repeat homology; immunoglobulin homology;

Query Match 14.4%; Score 90; DB 2; Length 6831;
Best Local Similarity 24.0%; Pred. No. 8;
Matches 23; Conservative 21; Mismatches 40; Indels 12; Gaps 3;

Qy 7 RAPDFLSEDDQVLRPALGSSVALNCTAMVYSGPHCLSPVQWLKDGPLGIGHYSLH 66
Db 101 RGPSTFV--GKPRITPKDGGALIVMECKV-----KSASTPVAKMKDGVPLSMGLYHA-- 151

Qy 67 YSWKANLSEVLVSVLVGVNTSTEVYGAFTCSION 102
Db 152 --IFSDLGQGYTLQLEIRGPSSSDAGQYRCNIRN 184

RESULT 4
A:Accession: S57242
A:Title: twitchin [similarity] - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C>Date: 28-Oct-1995 #sequence_revision 24-Oct-1997 #text_change 20-Jun-2000
C:Accession: S57242; S07571; S06797; S57218; T27934; T28030
R:Benian, G.M.; L'Hernault, S.W.; Morris, M.E.
Submitted to the EMBL Data Library, February 1993
A:Description: Additional sequence complexity within twitching of Caenorhabditis elegans
A:Reference number: S57242
A:Accession: S57242
A:Molecule type: DNA
A:Residues: 1-6839 <BEN1>
A:Cross-references: EMBL:L10351
A:Experimental source: var. Bristol
R:Benian, G.
Submitted to the EMBL Data Library, November 1989
A:Reference number: S07571
A:Accession: S07571
A:Molecule type: DNA
A:Residues: 792-6839 <BEN2>
A:Cross-references: EMBL:X15423; NID:96697; PIDN:CA93463.1; PID:966898
R:Benian, G.M.; Kiff, J.E.; Neckelmann, N.; Moerman, D.G.; Waterston, R.H.

Nature 342, 45-50, 1989
A:Title: Sequence of an unusually large protein implicated in regulation of myosin ac
A:Reference number: S06797; MID:90044042; PMID:2812002
A:Accession: S06797
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 806-1175;1178-1998,'Y',2000-3040,'I',3042-3335,'Y',3337-5693;5696-6359,'I
A:Cross-references: EMBL:X15423
A:Experimental source: var. Bristol
R:Benian, G.M.; L'Hernault, S.W.; Morris, M.E.
Genetics 134, 1097-1104, 1993
A:Title: Additional sequence complexity in the muscle gene, unc-22, and its encoded p
A:Reference number: S57218; MID:93387664; PMID:8397135
A:Accession: S57218
A:Molecule type: DNA
A:Residues: 2-99;108-194,'Q',196-206;374-468;658-753 <BEN4>
A:Experimental source: var. Bristol
R:White, S.
Submitted to the EMBL Data Library, May 1996
A:Reference number: Z20442
A:Accession: T27934
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 'MGIGKCKQ',19-6839 <WIL>
A:Cross-references: EMBL:Z73897; PIDN:CA98064.1; GSPDB:GN00022; CESP:ZK617.1a
A:Experimental source: clone ZK617
R:Harits, B.
Submitted to the EMBL Data Library, May 1996
A:Reference number: Z20458
A:Accession: T28030
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 'MGIGKCKQ',19-6839 <WT2>
A:Cross-references: EMBL:Z73899; PIDN:CA98081.1; GSPDB:GN00022; CESP:ZK617.1a
A:Experimental source: clone ZK629
C:Comment: Lack of unc-22 leads to a constant twitching of the body muscles.
C:Genetics:
A:Gene: unc-22; CESP:ZK617.1a
A:Map position: 4
A:Insertions: 18/3; 69/3; 143/2; 176/3; 264/2; 387/3; 413/2; 471/1; 516/3; 550/3; 582/3;
152/3; 6691/3; 6776/1; 6808/3
C:Superfamily: twitchin; fibronectin type III repeat homology; immunoglobulin homology
C:Keywords: ATP; autophosphorylation; duplication; muscle; phosphotransferase; serine
F:806-998,899-990,991-1083,1084-1175,1178-1273,1474-1567,1770-1864,2066-2158,2358-245
96-5790,6263-6356,6386-6478,6541-6635,6649-6742,6745-6838/Region: motif 2
F:1274-1372,1373-1473,1568-1670,1671-1769,1865-1964,1965-2065,2159-2258,2259-2357,245
23,4215-4313,4314-4415,4416-4516,4612-4710,4711-4811,4908-5009,5010-5109,5110-5210,53
F:5940-6197/Domain: protein kinase homology <KIN>
F:5948-5956/Region: protein kinase ATP-binding motif
F:5971/Active site: Lys #status predicted

Query Match 14.4%; Score 90; DB 2; Length 6839;
Best Local Similarity 24.0%; Pred. No. 8;
Matches 23; Conservative 21; Mismatches 40; Indels 12; Gaps 3;

Qy 7 RAPDFLSEDDQVLRPALGSSVALNCTAMVYSGPHCLSPVQWLKDGPLGIGHYSLH 66
Db 109 RGPSTFV--GKPRITPKDGGALIVMECKV-----KSASTPVAKMKDGVPLSMGLYHA-- 159

Qy 67 YSWKANLSEVLVSVLVGVNTSTEVYGAFTCSION 102
Db 160 --IFSDLGQGYTLQLEIRGPSSSDAGQYRCNIRN 192

RESULT 5
A:Accession: T27935
A:Title: hypothetical protein ZK617.1b - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C>Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 11-Jan-2000
C:Accession: T27935; T28031
R:White, S.
Submitted to the EMBL Data Library, May 1996
A:Reference number: Z20442

A:Accession: T27935
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-7160 <WIL>
A:Cross-references: EMBL:Z73897; PIDN:CAA98065.1; GSPDB:GN00022; CESP:ZK617.1b
A:Experimental source: clone ZK617
R:Harris, B.
submitted to the EMBL Data Library, May 1996
A:Accession: T28031
A:Reference number: Z20458
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-7160 <WIL>
A:Cross-references: EMBL:Z73899; PIDN:CAA98082.1; GSPDB:GN00022; CESP:ZK617.1b
A:Experimental source: clone ZK829
C:Genetics:
A:Gene: CESP:ZK617.1b
A:Map position: 4
A:Introns: 10/3; 61/3; 135/2; 168/3; 256/2; 379/3; 405/2; 463/1; 508/3; 542/3; 574/3; 597/1; 3141/3; 3269/1; 6473/3; 7012/3; 7097/1; 7129/3
C:Superfamily: twitchin; fibronectin type III repeat homology; immunoglobulin homology;

Query Match 14.4%; Score 90; DB 2; Length 7160;
Best Local Similarity 24.0%; Pred. No. 8.4;
Matches 23; Conservative 21; Mismatches 40; Indels 12; Gaps 3;

OY 7 RAPDLPSPEDVLRPALGSSVALNCTAMVWSGPHCSLPVQWMLDGLPLGIGHYSLHE 66
Db 101 KRPSPV--GKPRIPKDGALVMECKV---KSASTPVAKMKDGVLSKGLYHA-- 151
OY 67 YSMVKANLSEVLSSVLGVNVTSTFVYGAFTCSION 102
Db 152 ---IFSDLGDOTYLCQLEIRGSSSDACQYRCNIRN 184

RESULT 6
T20992
hypothetical protein F15G9.4a - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 18-Feb-2000
A:Accession: T20992; T24733
R:Sulston, J.
submitted to the EMBL Data Library, December 1994
A:Reference number: Z19355
A:Accession: T20992
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-5175 <WIL>
A:Cross-references: EMBL:Z47068; PIDN:CAA87335.1; GSPDB:GN00028; CESP:F15G9.4a
A:Experimental source: clone F15G9
R:Kershaw, J.
submitted to the EMBL Data Library, December 1994
A:Reference number: Z19929
A:Accession: T24733
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-5175 <WIL>
A:Cross-references: EMBL:Z47070; PIDN:CAA87344.1; GSPDB:GN00028; CESP:F15G9.4a
A:Experimental source: clone T09B9
C:Genetics:
A:Gene: CESP:F15G9.4a
A:Map position: X
A:Introns: 85/1; 120/1; 334/3; 370/1; 477/2; 606/3; 664/1; 935/3; 977/1; 1051/3; 1184/3; 2512/2; 2593/3; 2699/3; 2759/1; 2852/1; 2889/3; 2913/3; 2941/1; 2967/3; 2991/3; 3033/1; 4225/1; 4361/1; 4408/1; 4456/1; 4498/1; 4647/3; 4838/1; 4879/1; 4941/1; 5011/1; 5077/1

Query Match 14.0%; Score 87.5; DB 2; Length 5175;
Best Local Similarity 28.1%; Pred. No. 10;
Matches 32; Conservative 15; Mismatches 38; Indels 29; Gaps 6;

OY 1 MPG-----VCDRAPDLPSPEDVLRPALGSSVALNCTAMVWSGPHCSLPVQWMLDG 53
Db 4555 MGPFRSSRTVLHHAPOFIVKPKNTT--AATGAIYELRCSA--AGPPH---PTIWMADG 4607

OY 54 IPLGIGHYSLHEYSWVKANLSEVLSSVLGVNVTSTFVYGAFTCSIONISPS 107
Db 4608 -----KLIEDSKFEIAYSH-LKVTLNSTSDSGERTCMAONSVCSS 4646

RESULT 7
T43290
hemiscitin precursor - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C:Date: 11-Jan-2000 #sequence_revision 11-Jan-2000 #text_change 18-Feb-2000
A:Accession: T43290; T20993; T24734
R:Voegel, B.E.; Hedecock, E.M.
submitted to the EMBL Data Library, June 1998
A:Description: Hemiscitin is required for hemidesmosome mediated cell adhesion and ge
A:Reference number: Z22396
A:Accession: T43290
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-5198 <VOG>
A:Cross-references: EMBL:AF074901; PIDN:AAC26792.1
R:Sulston, J.
submitted to the EMBL Data Library, December 1994
A:Reference number: Z19355
A:Accession: T20993
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-5198 <WIL>
A:Cross-references: EMBL:Z47068; PIDN:CAA87336.1; GSPDB:GN00028; CESP:F15G9.4b
A:Experimental source: clone F15G9
R:Kershaw, J.
submitted to the EMBL Data Library, December 1994
A:Reference number: Z19929
A:Accession: T24734
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-5198 <WIL>
A:Cross-references: EMBL:Z47070; PIDN:CAA87345.1; GSPDB:GN00028; CESP:F15G9.4b
A:Experimental source: clone T09B9
C:Genetics:
A:Gene: him-4; F15G9.4b
A:Map position: X
A:Introns: 85/1; 120/1; 334/3; 370/1; 477/2; 606/3; 664/1; 935/3; 977/1; 1051/3; 1184/3; 2512/2; 2593/3; 2699/3; 2759/1; 2852/1; 2889/3; 2913/3; 2941/1; 2967/3; 2991/3; 3033/1; 4225/1; 4361/1; 4408/1; 4456/1; 4498/1; 4647/3; 4838/1; 4902/1; 4964/1; 5034/1; 51

Query Match 14.0%; Score 87.5; DB 2; Length 5198;
Best Local Similarity 28.1%; Pred. No. 10;
Matches 32; Conservative 15; Mismatches 38; Indels 29; Gaps 6;

OY 1 MPG-----VCDRAPDLPSPEDVLRPALGSSVALNCTAMVWSGPHCSLPVQWMLDG 53
Db 4555 MGPFRSSRTVLHHAPOFIVKPKNTT--AATGAIYELRCSA--AGPPH---PTIWMADG 4607

OY 54 IPLGIGHYSLHEYSWVKANLSEVLSSVLGVNVTSTFVYGAFTCSIONISPS 107
Db 4608 -----KLIEDSKFEIAYSH-LKVTLNSTSDSGERTCMAONSVCSS 4646

RESULT 8
AE3507
amidotransferase hish (EC 2.4.2.-) [imported] - Brucella melitensis (strain 16M)
C:Species: Brucella melitensis
C:Date: 01-Feb-2002 #sequence_revision 01-Feb-2002 #text_change 15-Feb-2002
A:Accession: AE3507
R:DelVecchio, V.G.; Kapatali, V.; Redkar, R.J.; Patra, G.; Mujer, C.; Ios, T.; Ivanov
Proc. Natl. Acad. Sci. U.S.A. 99, 443-448, 2002
A:Title: The genome sequence of the facultative intracellular pathogen Brucella melit
A:Reference number: AD3252; PMID:1175688
A:Accession: AE3507
A:Status: preliminary
A:Molecule type: DNA

A:Residues: 1-244 <KUR>
 A:Cross-references: GB:AE008917, PIDN:AAL53224.1; PID:g17984101; GSPDB:GN00190
 C:Genetics:
 A:Gene: BME12043
 A:Map Position: 1
 C:Superfamily: amido transferase; pentosyl transferase
 C:Keywords: glycosyl transferase; pentosyl transferase

Query Match
 Best Local Similarity 13.3%; Score 83.5; DB 2; Length 244;
 Matches 33; Conservative 13; Mismatches 43; Indels 45; Gaps 6;

QY 1 MGV-----CDRADFLSPSEDVLT--RPAIGSSVAL-----NCTAW 35
 DB 78 LFGVGVAYDCRRGLDAVGAVNEALNDVYLKKARPLIGICVGMQIMSERGLEKTVTNGLGW 137
 QY 36 VV-----SGPHCSLPSVQW-----LKDGLPLIGIG--HSLHEYGMVAKANLS 75
 DB 138 IAGDVRENVPSDASLTKITPQIGMNRHVKHSHPIFDGIPDGDLHAFVHVMWLAKNNS 197
 QY 76 EVLVSSVYLGVAVTS 89
 DB 198 DLAVTVDYGDDVTA 211

RESULT 9
 S50065
 C:Species: Mus musculus (house mouse)
 C>Date: 07-May-1995 #sequence_revision 21-Jul-1995 #text_change 05-Nov-1999
 C:Accession: S50065
 R:Crocker, P. R.; Mucklow, S.; Bouckson, V.; McWilliam, A.; Willis, A. C.; Gordon, S.; Mill
 EMBD J. 13, 4490-4503, 1994
 A:Title: Sialoadhesin, a macrophage sialic acid binding receptor for haemopoietic cells
 A:Reference number: S50065; MUID:95009950; PMID:7925291
 A:Accession: S50065
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-1694 <CRO>
 A:Cross-references: EMBL:Z36293; NID:9557253; PIDN:CAAB5290.1; PID:9557254

Query Match
 Best Local Similarity 13.3%; Score 83.5; DB 2; Length 1694;
 Matches 37; Conservative 17; Mismatches 42; Indels 75; Gaps 6;

QY 12 LSPSEDOYLRLPALGSSVALNCTAWVSGPHCSLPSVQWMLKDGLPLIGIGH----- 61
 DB 246 LSSSGRNILP---GDPVLTLCR---VNSYPVAVSAVGMADGVALGVYTGHLRLFSAMNN 299
 QY 62 -----YSLH-----EY 67
 DB 300 DSGAVTCAATNDMGSLVSSPLSLHFVMAEYKMPAGVLENETVTLCTSPKEAPQELRY 359
 QY 68 SWAKN-LSEVLVSSVGVAVNTSTEVYGAFTCSIONISSESTFLQAGPTS 117
 DB 360 SWYRNHLLLEDAHASTLHLPAVTRADGFEYCEVQNAQS-----ENSSPLS 406

RESULT 10
 I37202
 B:CAM protein - human
 C:Species: Homo sapiens (man)
 C>Date: 12-Aug-1996 #sequence_revision 12-Aug-1996 #text_change 21-Jul-2000
 C:Accession: I37202; S47272
 R:Campbell, I. G.; Foulkes, W. D.; Senger, G.; Trowsdale, J.; Garin-Chesa, P.; Rettig, W. J.
 Campbell, I. G.; Foulkes, W. D.; Senger, G.; Trowsdale, J.; Garin-Chesa, P.; Rettig, W. J.
 A:Title: Molecular cloning of the B-CAM cell surface glycoprotein of epithelial cancers:
 A:Reference number: I37202; MUID:95042297; PMID:7954395
 A:Accession: I37202
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-368 <RES>

A:Cross-references: EMBL:X80026; NID:9535178; PIDN:CAAB56327.1; PID:9535179
 C:Genetics:
 A:Gene: B-CAM

Query Match
 Best Local Similarity 13.1%; Score 82; DB 2; Length 588;
 Matches 29; Conservative 12; Mismatches 33; Indels 6; Gaps 3;

QY 10 DFLSPSEDOYLRLPALGSSVALNCTAWVSGPHCSLPSVQWMLKDGLPLIGIGHYSLHYSW 69
 DB 362 DPLELSEGVKVLSTPLNSAVVNCN---VHG--LPTPALRWTKDSTPLDGPMLSLSTIF 416
 QY 70 VKANLSEVLVSSVYLGVAVTS 89
 DB 417 -DSNGTYVCASLPTVPVLS 435

RESULT 11
 I38000
 C:Species: Homo sapiens (man)
 C>Date: 09-Mar-1996 #sequence_revision 09-Mar-1996 #text_change 05-Nov-1999
 C:Accession: I38000; S51663
 R:Parsons, S. F.; Mallinson, G.; Holmes, C. H.; Houlihan, J. M.; Simpson, K. L.; Mawby, W.
 Proc. Natl. Acad. Sci. U.S.A. 92, 5496-5500, 1995
 A:Title: The Lutheran blood group glycoprotein, another member of the immunoglobulin
 A:Reference number: I38000; MUID:95296337; PMID:7777537
 A:Accession: I38000
 A:Molecule type: mRNA
 A:Residues: 1-628 <RES>
 A:Cross-references: EMBL:X83425; NID:9603559; PIDN:CAAB58449.1; PID:9603560
 A:Note: parts of this sequence, including the amino end of the mature form, were conf
 A:Genetics:
 A:Gene: GDB:LU
 A:Cross-references: GDB:120155; OMIM:111200
 A:Map position: 19q12-19q13
 A:Keywords: glycoprotein
 F.1-31/20man: signal sequence #status predicted <SIG>
 F.32-628/Product: Lutheran blood group glycoprotein #status experimental <MAT>

Query Match
 Best Local Similarity 13.1%; Score 82; DB 2; Length 628;
 Matches 29; Conservative 12; Mismatches 33; Indels 6; Gaps 3;

QY 10 DFLSPSEDOYLRLPALGSSVALNCTAWVSGPHCSLPSVQWMLKDGLPLIGIGHYSLHYSW 69
 DB 362 DPLELSEGVKVLSTPLNSAVVNCN---VHG--LPTPALRWTKDSTPLDGPMLSLSTIF 416
 QY 70 VKANLSEVLVSSVYLGVAVTS 89
 DB 417 -DSNGTYVCASLPTVPVLS 435

RESULT 12
 JCI450
 N:Contamin: growth factor receptor 4 - rat
 C:Species: Rattus norvegicus (Norway rat)
 C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 01-Dec-2000
 C:Accession: JCI450; PT0191
 R:Horlick, R. A.; Stack, S. L.; Cooke, G. M.
 Gene 120, 291-295, 1992
 A:Title: Cloning, expression and tissue distribution of the gene encoding rat fibrobl
 A:Reference number: JCI450; MUID:93013049; PMID:1398143
 A:Accession: JCI450
 A:Molecule type: mRNA
 A:Residues: 1-650 <HOR>
 A:Cross-references: GB:M91599; NID:9204137; PIDN:AAA41157.1; PID:9204138
 R:lat, C.; Lemke, G.
 Neuron 6, 691-704, 1991
 A:Title: An extended family of protein-tyrosine kinase genes differentially expressed
 A:Reference number: PT0183; MUID:91222560; PMID:2025425
 A:Accession: PT0191

A:Molecule type: mRNA
A:Residues: 465-518 <LA1>
A:Experimental source: sciatic nerve
C:Genetics:
A:Gene: FGFR4; tyro-9
C:Function:
A:Description: receptor mediating effects of fibroblast growth factor
A:Note: expressed in normal lung; expressed in some carcinomas
C:Superfamily: basic fibroblast growth factor receptor 1; immunoglobulin homology; prote
C:Keywords: ATP; autophosphorylation; duplication; glycoprotein; growth factor receptor;
F:11-72/Domain: immunoglobulin homology <IM1>
F:110-181/Domain: immunoglobulin homology <IM2>
F:218-238/Domain: transmembrane #status predicted <TM>
F:239-650/Domain: intracellular #status predicted <INT>
F:313-598/Domain: protein kinase homology <KIN>
F:321-329/Region: protein kinase ATP-binding motif
F:104,116,157,168/Binding site: carbonylstrate (Asn) (covalent) #status predicted
F:351,368,460/Active site: Lys, Glu, Asp #status predicted
F:55,478/Binding site: magnesium (Asn, Asp) #status predicted
F:1/Binding site: phosphate (Tyr) (covalent) (by autophosphorylation) #status predicted

Query Match 13.0%; Score 81.5; DB 1; Length 650;
Best Local Similarity 31.9%; Pred. No. 3.6;
Matches 29; Conservative 11; Mismatches 36; Indels 15; Gaps 4;

Oy 24 LGSSVALNCTAMVYSGPHCSLPYQWLK----DGLPLIGGHYSLHEYSWKANLSEVLV 79
Db 109 VGSNVELCKKYSDQPH-----IQWLKHVYINGSSFGADGPPYQVLKTTDINSEV-- 161

Oy 80 SSVLGAVNTSTEVYGAFTCSION--ISFSS 107
Db 162 -EVLILRVNSADAGEYTCLAGNSIGLSYQS 191

RESULT 13
Ig lambda-like chain, V-C region - nurse shark
A:Accession: A49633
C:Species: Ginglymostoma cirratum (nurse shark)
C:Date: 07-Apr-1994 #sequence_revision 18-Nov-1994 #text_change 21-Jan-2000
C:Accession: A49633
R:Greenberg, A.S.; Steiner, L.; Kasahara, M.; Flajnik, M.F.
Proc. Natl. Acad. Sci. U.S.A. 90, 10603-10607, 1993
A:Title: Isolation of a shark immunoglobulin light chain cDNA clone encoding a protein r
A:Reference number: A49633; MUID:94068449; PMID:8248152
A:Accession: A49633
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-238 <GRE>
A:Experimental source: spleen
A:Note: sequence extracted from NCBI backbone (NCBIN:141012, NCBIIP:141013)
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:36-110/Domain: immunoglobulin homology <IM>

Query Match 12.9%; Score 81; DB 2; Length 238;
Best Local Similarity 29.3%; Pred. No. 1.2;
Matches 29; Conservative 18; Mismatches 36; Indels 16; Gaps 3;

Oy 12 LSPSEDOVLRPALGSSVALNCTAMVYSGPHCSLP--SVQWLKDGSLPLIGGHYSLHEYS 68
Db 141 LPPSPDOVQTKG-----TATLVCLANHFYPDELQVQWKKDGAVIDSDVQTS----N 187

Oy 69 WYKANLSEVLVSVGLVAVTSTEVYGAFTCSIONISFSS 107
Db 188 LTRASDSTYSVSLTLTSGSDMESNARPSCALTHVTLS 226

RESULT 14
S18209
fibroblast growth factor receptor 4 precursor (clone 61) - mouse
A:Alternate names: tyrosine kinase Mpk-11
N:Contains: protein-tyrosine kinase (EC 2.7.1.112)
C:Species: Mus musculus (house mouse)
C:Date: 07-Oct-1994 #sequence_revision 07-Oct-1994 #text_change 16-Jul-1999

C:Accession: S18209; S26751; S30497
R:Stark, K.L.; McMahon, J.A.; McMahon, A.P.
Development 113, 641-651, 1991
A:Title: FGFR-4, a new member of the fibroblast growth factor receptor family, expres
A:Reference number: S18209; MUID:92146274; PMID:1723680
A:Accession: S18209
A:Molecule type: mRNA
A:Residues: 1-799 <STRA1>
A:Cross-references: EMBL:X59927
R:Stark, K.L.
submitted to the EMBL Data Library, May 1991
A:Reference number: S26751
A:Accession: S26751
A:Molecule type: mRNA
A:Residues: 1-485, 'QVYRAAE', 486-799 <STRA2>
A:Cross-references: EMBL:X59927; NID:950968; PIDN:CAAA2551.1; PID:950969
R:Giliardi-Hebenstreit, P.; Nieto, M.A.; Frain, M.; Mattei, M.G.; Chestler, A.; Wilkin
Oncogene 7, 2499-2506, 1992
A:Title: An Eph-related receptor protein tyrosine kinase gene segmentally expressed i
A:Reference number: S30496; MUID:93096484; PMID:1281307
A:Accession: S30497
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 611-667 <GIL>
A:Cross-references: EMBL:X57236; NID:953187; PIDN:CAAA0512.1; PID:953188
C:Superfamily: basic fibroblast growth factor receptor 1; immunoglobulin homology; pr
C:Keywords: ATP; duplication; glycoprotein; growth factor receptor; phosphotransferas
F:1-18/Domain: signal sequence #status predicted <SIG>
F:19-799/Product: fibroblast growth factor receptor 4 #status predicted <ANT>
F:19-366/Domain: extracellular #status predicted <EXT>
F:162-223/Domain: immunoglobulin homology <IM>
F:367-387/Domain: transmembrane #status predicted <TM>
F:388-799/Domain: intracellular #status predicted <INT>
F:462-747/Domain: protein kinase homology <KIN>
F:470-478/Region: protein kinase ATP-binding motif
F:54-98,169-221,268-330/Disulfide bonds: #status predicted
F:500,517,609/Active site: Lys, Glu, Asp #status predicted

Query Match 12.9%; Score 80.5; DB 2; Length 799;
Best Local Similarity 30.8%; Pred. No. 5.7;
Matches 28; Conservative 11; Mismatches 37; Indels 15; Gaps 4;

Oy 24 LGSSVALNCTAMVYSGPHCSLPYQWLK----DGLPLIGGHYSLHEYSWKANLSEVLV 79
Db 260 VGSNVELCKKYSDQPH-----IQWLKHVYINGSSFGADGPPYQVLKTTDINSEV-- 312

Oy 80 SSVLGAVNTSTEVYGAFTCSION--ISFSS 107
Db 313 -QVILILRVNSADAGEYTCLAGNSIGLSYQS 342

RESULT 15
S20901
titin - rabbit (fragment)
C:Species: Oryctolagus cuniculus (domestic rabbit)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 18-Jun-1999
C:Accession: S20901; I46520
R:Laibin, S.; Gautel, M.; Lakey, A.; Trinick, J.
EMBO J. 11, 1711-1716, 1992
A:Title: Towards a molecular understanding of titin.
A:Reference number: S20897; MUID:92258380; PMID:1582406
A:Accession: S20901
A:Status: nucleic acid sequence not shown; translation not shown
A:Molecule type: mRNA
A:Residues: 1-6805 <LAB>
A:Cross-references: EMBL:X64696
A:Note: the nucleotide sequence was submitted to the EMBL Data Library, February 1992
R:Laibin, S.; Barlow, D.P.; Gautel, M.; Gibson, T.; Holt, J.; Hsieh, C.L.; Francke, U
Nature 345, 273-276, 1990
A:Title: A regular pattern of two types of 100-residue motif in the sequence of titin
A:Reference number: I46520; MUID:90238553; PMID:2129545
A:Accession: I46520
A:Status: translated from GR/EMBL/DBJ

A:Molecule type: mRNA
 A:Residues: 4235-5250 <LA2>
 A:Cross-References: EMBL:X17329; NID:q1756; PID:CAA35207.1; PID:g930251
 C:Superfamily: titin; fibronectin type III repeat homology; immunoglobulin homology; ptc
 C:Keywords: muscle

Query Match 12.9%; Score 80.5; DB 2; Length 6805;
 Best Local Similarity 24.4%; Pred. No. 70;
 Matches 21; Conservative 16; Mismatches 30; Indels 19; Gaps 3;

QY 36 VYSGPHCSLPYQWLKDLPLGIGSHYSLHEYSWKANISEVLVSSVGLGVNVTSTEVYGA 95
 DB 6197 VIGRR---FELFWYKDGEP-----RQTRVNVETATSTILIKESSKDDFGK 6243
 QY 96 FTCSIONT-----SFSSFTIORACP 115
 DB 6244 YTTATNSAGTATENLSYVLEKFGP 6269

Search completed: November 14, 2002, 17:31:48
 Elapsed time: 24 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 14, 2002, 16:48:52 : Search time 13 Seconds
(without alignments)
376.477 Million cell updates/sec

Title: US-09-598-443-2_COPY_1_118
Perfect score: 626
Sequence: 1 MFGVCDRAPPELSPSEDOVL.....SIGNISFSTLQKAGPTSH 118

Scoring table:
BLOSUM62
Gapop 10.0 , Gapext 0.5

Reached: 112892 seqs, 41476328 residues
Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SwisProt_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	90.5	14.5	1709	1 SN_HUMAN	Q9Z222 homo sapien
2	83.5	13.3	216	1 HRS5_BRUCE	O8Y235 bruceella me
3	83.5	13.3	1694	1 SN_MOUSE	O62230 mus musculu
4	82	13.1	628	1 LU_HUMAN	P50895 homo sapien
5	80.5	12.9	808	1 FGR4_MOUSE	Q03142 mus musculu
6	80	12.8	2012	1 DSCA_HUMAN	O64569 homo sapien
7	79.5	12.7	1242	1 NPHN_MOUSE	Q9G257 mus musculu
8	78.5	12.5	1234	1 NPHN_RAT	O9J044 rattus norv
9	76.5	12.2	802	1 FGR4_HUMAN	P22455 homo sapien
10	76.5	12.2	1142	1 MYPF_HUMAN	Q14324 homo sapien
11	76.5	12.2	1241	1 NPHN_HUMAN	O60500 homo sapien
12	76	12.1	602	1 PGL1_MOUSE	P22437 mus musculu
13	75.5	12.1	822	1 FGR1_HUMAN	P11362 homo sapien
14	75.5	12.1	822	1 FGR1_MOUSE	P16092 mus musculu
15	75	12.0	359	1 LACH_DROME	Q24372 drosophila
16	74.5	11.9	819	1 FGR1_CHICK	P21804 gallus gall
17	74	11.8	824	1 MUR1_HUMAN	Q9UDY8 homo sapien
18	73.5	11.7	1666	1 MYM1_MOUSE	O6G234 mus musculu
19	73	11.7	1447	1 DCC_MOUSE	P70211 mus musculu
20	73	11.7	806	1 TRIO_HUMAN	O75962 homo sapien
21	72.5	11.6	308	1 CERK2_CHICK	P14460 gallus gall
22	72	11.5	248	1 MYPO_HUMAN	P25189 homo sapien
23	72	11.5	333	1 AMAL_DROME	P13364 drosophila
24	72	11.5	873	1 FAS2_DROME	P34082 drosophila
25	72	11.5	987	1 K6P1_CANAL	O94201 candida alb
26	72	11.5	1070	1 PKT7_HUMAN	O13308 homo sapien
27	71.5	11.4	602	1 PGR1_RAT	O63921 rattus norv
28	71	11.3	654	1 BFR2_HUMAN	O01742 homo sapien
29	70.5	11.3	847	1 CD22_HUMAN	P20273 homo sapien
30	70.5	11.3	887	1 UFO_HUMAN	P30530 homo sapien
31	70.5	11.3	1897	1 P10F_HUMAN	P10586 homo sapien
32	70	11.2	365	1 CXAR_HUMAN	P78310 homo sapien
33	70	11.2	1447	1 DCC_HUMAN	P43146 homo sapien

34	69.5	11.1	327	1 XYNC_EMENT	Q00177 emericella
35	69.5	11.1	402	1 PAGE_RAT	O63495 rattus norv
36	69.5	11.1	498	1 VGLX_PRIVI	P07562 pseudorale
37	69.5	11.1	599	1 PGL1_HUMAN	P23219 homo sapien
38	69.5	11.1	888	1 MYPO_MOUSE	Q00993 mus musculu
39	69	11.0	248	1 MYPO_MOUSE	P27573 mus musculu
40	69	11.0	1010	1 SNR2_YEAST	P38163 saccharomyc
41	68.5	10.9	322	1 LDH8_FUNEA	P42122 fundulus pa
42	68.5	10.9	801	1 FGR3_MOUSE	O61851 mus musculu
43	68.5	10.9	806	1 FGR3_HUMAN	P22607 homo sapien
44	68.5	10.9	813	1 FGR2_XENLA	O03364 xenopus lae
45	68.5	10.9	822	1 FGR1_RAT	Q04589 rattus norv

ALIGNMENTS

RESULT 1
ID SN_HUMAN STANDARD: PRT: 1709 AA.
AC Q9Z222; Q9H1H6; Q9H1H7; Q9H7L7; Q9GZ55;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Sialoadhesin precursor (Sialic acid binding Ig-like lectin-1) (Siglec-1) (CD169 antigen).
CN SN.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
SEQUENCE FROM N.A. (ISOFORM 1).
RP Hartnell A., Steel J., Turley H., Jones M., Jackson D., Crocker P.R.;
RT "Characterisation of human sialoadhesin (Siglec-1), a sialic acid binding receptor expressed on resident and inflammatory macrophage populations."
RT Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.
RN [2]
RN SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
RP MEDLINE=21638749; PubMed=11780052;
RX Deloukas P., Matthews L.H., Ashurst J., Burton J., Gilbert J.G.R., Jones M., Stavrides G., Almeida J.P., Babbage A.K., Baggeley C.L., Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., Graham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., Levaslatio M.H., Laversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., Marsh V.L., Martin S.L., McConachie L.J., McJay K., McMorris A.A., Milne S.A., Misty D., Moore M.J.F., Mullikin J.C., Nickerson T., Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., Phillimore B.J.C.T., Scott C.E., Sehra H.K., Showkhen R.W., Ramsay H., Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Showkhen R.W., Ramsay H., Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sultson J.E., Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., Triomans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., Whitaker P., Willey D.L., Williams L., Williams S.A., Wilming L., Way P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT "The DNA sequence and comparative analysis of human chromosome 20."
RL Nature 414:865-871(2001).
[3]
SEQUENCE OF 733-1709 FROM N.A. (ISOFORMS 1 AND 2).
RP TISSUE=Spleen;
RC Ohara O., Nagase T., Kikuno R., Okumura K.;
RA "The nucleotide sequence of a long cDNA clone isolated from human

[illegible]

FT	DOMAIN	525	583		IG-LIKE C2-TYPE DOMAIN 5.
FT	DOMAIN	698	692		IG-LIKE C2-TYPE DOMAIN 6.
FT	DOMAIN	718	777		IG-LIKE C2-TYPE DOMAIN 7.
FT	DOMAIN	806	879		IG-LIKE C2-TYPE DOMAIN 8.
FT	DOMAIN	904	962		IG-LIKE C2-TYPE DOMAIN 9.
FT	DOMAIN	993	1069		IG-LIKE C2-TYPE DOMAIN 10.
FT	DOMAIN	1095	1151		IG-LIKE C2-TYPE DOMAIN 11.
FT	DOMAIN	1181	1243		IG-LIKE C2-TYPE DOMAIN 12.
FT	DOMAIN	1269	1326		IG-LIKE C2-TYPE DOMAIN 13.
FT	DOMAIN	1355	1428		IG-LIKE C2-TYPE DOMAIN 14.
FT	DOMAIN	1455	1515		IG-LIKE C2-TYPE DOMAIN 15.
FT	DOMAIN	1544	1617		IG-LIKE C2-TYPE DOMAIN 16.
FT	SITE	821	829		CELL ATTACHMENT SITE (POTENTIAL).
FT	DISULFID	161	98		
FT	DISULFID	160	218		BY SIMILARITY.
FT	DISULFID	263	306		BY SIMILARITY.
FT	DISULFID	347	391		BY SIMILARITY.
FT	DISULFID	434	492		BY SIMILARITY.
FT	DISULFID	532	576		BY SIMILARITY.
FT	DISULFID	625	685		BY SIMILARITY.
FT	DISULFID	725	770		BY SIMILARITY.
FT	DISULFID	813	872		BY SIMILARITY.
FT	DISULFID	911	955		BY SIMILARITY.
FT	DISULFID	1000	1062		BY SIMILARITY.
FT	DISULFID	1102	1144		BY SIMILARITY.
FT	DISULFID	1188	1236		BY SIMILARITY.
FT	DISULFID	1276	1319		BY SIMILARITY.
FT	DISULFID	1362	1421		BY SIMILARITY.
FT	DISULFID	1462	1508		BY SIMILARITY.
FT	DISULFID	1551	1610		BY SIMILARITY.
FT	CARBOHYD	159	159		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	266	266		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	299	299		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	340	340		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	500	500		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	583	583		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	693	693		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	722	722		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	737	737		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	882	882		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1086	1086		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1099	1099		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1246	1246		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1459	1459		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1473	1473		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	VARSPLIC	326	340		MAEVANAGVLEN -> SESWRRLRGVSGKH (IN ISOFORM 2).
FT	VARSPLIC	341	1694		MISSING (IN ISOFORM 2).
FT	VARSPLIC	1528	1598		YPPKPLDTLVEEFGGHQIIDLDRUDESLATILLRGSQ LVASQHLDAEPKPIHVTAPNPAIRVDIE -> CEYEIS ALCLSLHLGPGYQAFSSAQSCKPGLKRLTASLAGCMF VSMIDGYPALPKRIILLPWDEXRR (IN ISOFORM 3).
FT	VARSPLIC	1599	1694		MISSING (IN ISOFORM 3).
FT	CONFLICT	590	590		P -> Q (IN REF. 1; AA SEQUENCE).
FT	CONFLICT	1049	1051		IHF -> Q (IN REF. 1; AA SEQUENCE).
FT	CONFLICT	1054	1055		LE -> YV (IN REF. 1; AA SEQUENCE).
FT	CONFLICT	1061	1061		T -> Q (IN REF. 1; AA SEQUENCE).
FT	CONFLICT	1065	1065		S -> Q (IN REF. 1; AA SEQUENCE).
SO	SEQUENCE	1694 AA;	183087 MW;		1D2FBF39B7299CBC CRC64;
					Query Match 13.3%; Score 83.5; DB 1; Length 1694;
					Best Local Similarity 21.6%; Pred. No. 2.1;
					Matches 37; Conservative 17; Mismatches 42; Indels 75; Gaps
Oy	12	LSPDEOVLPALGGSAALNCATAMVVSQGHCSLTVOWLKXGDLPLGGG-----	61		
Dd	246	LSSGRILP---GDPTILCR---VNSSYPAVSAVMQARGVNLGVTHLRFRFSAAWN	299		
Oy	62	-----YSLH-----	67		
Dd	300	DSCAITCOATINDGSLVSSPLSIHTPMAEVKNNPAGPVLENYITLLCSTPRKEAPOELRY	359		
Oy	68	SWKAN--LSKVLYSVLVGNVNTSTEYGAFTCSIIONISSFFSFLTORAGPTS	117		

```

Db 360 SWKXNHILIEDAHASTLHPAVYRADTGTGYFCEYONAGS-----ERSSPLS 406

RESULT 4
LU_HUMAN
ID LU_HUMAN STANDARD: PRT: 628 AA.
AC P50895
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Lutheran blood group glycoprotein precursor (B-CAM cell surface
DE glycoprotein) (Aubberger B antigen) (F8/G25 antigen).
DE LU OR BCM OR MSK19.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;

[1]
RN RN SEQUENCE FROM N.A., AND SEQUENCE OF 32-67 AND 182-203.
RC TISSUE-Placenta;
RX MEDLINE-95296337; PubMed-7777537;
RA Parsons S.F., Mallinson G., Holmes C.H., Houlihan J.M., Simpson K.L.,
RA Mawby W.J., Spurr N.K., Warne D., Barclay A.N., Anstee D.J.;
DE "The Lutheran blood group glycoprotein, another member of the
DE immunoglobulin superfamily, is widely expressed in human tissues and
DE is developmentally regulated in human liver."
RT Proc. Natl. Acad. Sci. U.S.A. 92:5496-5500(1995).
RL [2]
RN RN SEQUENCE OF 1-588 FROM N.A.
RX MEDLINE-95042297; PubMed-7954395;
RA Campbell I.G., Foulkes W.D., Senger G., Trowsdale J.,
RA Garin-Chesa P., Rettig W.J.;
DE "Molecular cloning of the B-CAM cell surface glycoprotein of
DE epithelial cancers: a novel member of the immunoglobulin
DE superfamily."
RT Cancer Res. 54:5761-5765(1994).
RL -1- FUNCTION: PROBABLE RECEPTOR. MAY MEDIATE INTRACELLULAR SIGNALING.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- TISSUE SPECIFICITY: WIDE TISSUE DISTRIBUTION. (HIGHEST IN THE
CC PANCREAS AND VERY LOW IN BRAIN). CLOSELY ASSOCIATED WITH THE BASAL
CC LAYER OF CELLS IN EPITHELIA AND THE ENDOTHELIUM OF BLOOD VESSEL
CC WALLS.
CC -1- DEVELOPMENTAL STAGE: IS UNDER DEVELOPMENTAL CONTROL IN LIVER AND
CC MAY ALSO BE REGULATED DURING DIFFERENTIATION IN OTHER TISSUES.
CC UPREGULATED FOLLOWING MALIGNANT TRANSFORMATION IN SOME CELL TYPES.
CC -1- POLYMORPHISM: LU IS RESPONSIBLE FOR THE LUTHERAN BLOOD GROUP
CC SYSTEM.
CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
CC -1- SIMILARITY: CONTAINS 2 IMMUNOGLOBULIN-LIKE V-TYPE DOMAINS.
CC
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on ways
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL: X83425; CAA58449.1; -.
CC EMBL: X80026; CAA56327.1; -.
CC Genew: HGNC:6722; LU.
CC MIM: 111200; -.
CC
CC InterPro: IPR003006; IG_MHC.
CC InterPro: IPR003598; IG_C2.
CC InterPro: IPR003600; IG_like.
CC Pfam: PF00047; Ig_5.
CC SMART: SM00410; IG_like; 2.
CC SMART: SM00408; JcC2; 2.
CC Receptor: Immunoglobulin domain; Glycoprotein; Transmembrane; Signal;
CC Repeat; Blood group antigen.
CC
CC 31
CC

```

```
FT CHAIN 32 628 LUTHERAN BLOOD GROUP GLYCOPROTEIN.
FT DOMAIN 32 547 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 548 568 POTENTIAL.
FT DOMAIN 569 628 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 46 132 IG-LIKE V-TYPE DOMAIN 1.
FT DOMAIN 165 244 IG-LIKE V-TYPE DOMAIN 2.
FT DOMAIN 284 344 IG-LIKE C2-TYPE DOMAIN 1.
FT DOMAIN 377 431 IG-LIKE C2-TYPE DOMAIN 2.
FT DOMAIN 466 529 IG-LIKE C2-TYPE DOMAIN 3.
FT DISULFID 53 125 PROBABLE.
FT DISULFID 172 237 PROBABLE.
FT DISULFID 291 337 PROBABLE.
FT DISULFID 384 424 PROBABLE.
FT DISULFID 473 522 PROBABLE.
FT CARBOHYD 321 321 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 377 377 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 383 383 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 419 419 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 439 439 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CONFLICT 225 226 RL -> PC (IN REF. 2).
FT CONFLICT 355 356 EL -> DV (IN REF. 2).
SO SEQUENCE 628 AA: 67374 MW: C89B0A4835492B1E CRC64:

Query Match 13.1%; Score 82; DB 1; Length 628;
Best Local Similarity 36.2%; Pred. No. 0.95;
Matches 29; Conservative 12; Mismatches 33; Indels 6; Gaps 3;

OY 10 DELSSENOVLRPALGSSVALNCTAMVSGPHCSLPYQWLKGLPLIGHYSLHEYSW 69
Db 362 DPLEISEKGVLSLPLNSSAVNCS--VHG--LPPPALRWTKDPSLDGPMWLSLSITF 416
OY 70 VKANLEVLVSVLGVNTS 89
Db 417 -DSNCTVCEASLPPVPLVS 435

RESULT 5
ID FGR4_MOUSE STANDARD: PRT: 808 AA.
AC 003142:
DT 01-OCT-1994 (Rel. 30, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Fibroblast growth factor receptor 4 precursor (EC 2.7.1.112) (FGR-4)
DE (Protein-tyrosine kinase receptor MPR-11).
DE FGR4 OR FGR-4 OR MPR-11.
CN Mus musculus (Mouse).
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
NX NCBI_TaxID=10090;
OX (1)
RP SEQUENCE FROM N.A.
RC STRAIN-CD-1; TISSUE-Fetal cerebellum;
RX MEDLINE-92146274; Pubmed-1723680;
RA Stark K.L., McMahon J., McMahon A.P.;
RT "FGR-4, a new member of the fibroblast growth factor receptor
RT family, expressed in the definitive endoderm and skeletal muscle
RT lineages of the mouse.";
RL Development 113:641-651(1991).
RN (2)
RP SEQUENCE OF 620-676 FROM N.A.
RC STRAIN-C57BL/6; TISSUE-Embryonic brain;
RX MEDLINE-93096484; Pubmed-1281307;
RA Glazard-Hedenstreit P., Nieto M.A., Frain M., Mattei M.-G.,
RA Chetlier A., Wilkinson D.G., Charney P.;
RT "An Epi-related receptor protein tyrosine kinase gene segmentally
RT expressed in the developing mouse hindbrain.";
RL Oncogene 7:2499-2506(1992).
CC -1- FUNCTION: PUTATIVE RECEPTOR FOR BASIC FIBROBLAST GROWTH FACTOR.
CC MAY BE INVOLVED IN THE DEVELOPMENT OF SKELETAL MUSCLE CELL
CC LINEAGES.
CC -1- CATALYTIC ACTIVITY: ATP + a protein tyrosine - ADP + protein
CC tyrosine phosphate.
```

```
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- TISSUE SPECIFICITY: EXPRESSED IN THE DEVELOPING GUT ENDODERM,
CC IN MYOTOMALLY DERIVED SKELETAL MUSCLE, THE ADRENAL CORTEX,
CC KIDNEY AND CONDENSING CARTILAGE. PRESENT IN ADULT LIVER,
CC LUNG AND KIDNEY.
CC -1- SIMILARITY: BELONGS TO THE FIBROBLAST GROWTH FACTOR RECEPTOR
CC FAMILY.
CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC -----
CC EMBL: X59927; CAA42551.1; -.
CC EMBL: X57236; CAA40512.1; -.
CC HSSP: P11362; IEGK.
CC MGD: MGI:95525; Fgfr4.
CC InterPro: IPR000719; Euk_pkinase.
CC InterPro: IPR003006; Ig_MHC.
CC InterPro: IPR003598; Ig_C2.
CC InterPro: IPR01245; Tyr_pkinase.
CC Pfam: PF00047; Ig_3.
CC Pfam: PF00069; pkinase.
CC PRINTS: PR00109; TYRKINASE.
CC ProDom: PD000001; Euk_pkinase.1.
CC SMART: SM00408; IGC2_3.
CC SMART: SM00219; TyrcK_1.
CC PROSITE: PS00107; PROTEIN_KINASE_ATP_FALSE_NEG.
CC PROSITE: PS00109; PROTEIN_KINASE_TYR_1.
CC PROSITE: PS50011; PROTEIN_KINASE_DOM_1.
CC Receptor; Glycoprotein; Tyrosine-protein kinase; ATP-binding;
CC Transferase; Phosphorylation; Transmembrane; Immunoglobulin domain;
CC Repeat; Signal.
CC KW SIGNAL 1 18
CC FT CHAIN 19 808 FIBROBLAST GROWTH FACTOR RECEPTOR 4.
CC FT DOMAIN 19 366 EXTRACELLULAR (POTENTIAL).
CC FT TRANSMEM 367 387 POTENTIAL.
CC FT DOMAIN 388 808 CYTOPLASMIC (POTENTIAL).
CC FT DOMAIN 53 98 IG-LIKE C2-TYPE DOMAIN 1.
CC FT DOMAIN 169 221 IG-LIKE C2-TYPE DOMAIN 2.
CC FT DOMAIN 268 330 IG-LIKE C2-TYPE DOMAIN 3.
CC FT DOMAIN 464 761 PROTEIN KINASE.
CC FT NP_BIND 470 478 ATP (BY SIMILARITY).
CC FT BINDING 509 509 ATP (BY SIMILARITY).
CC FT ACT_SITE 618 618 BY SIMILARITY.
CC FT MOD_RES 649 649 PHOSPHORYLATION (AUTO-) (BY SIMILARITY).
CC FT DISULFID 53 98 POTENTIAL.
CC FT DISULFID 169 221 POTENTIAL.
CC FT DISULFID 268 330 POTENTIAL.
CC FT CARBOHYD 109 109 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 255 255 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 287 287 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 308 308 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 319 319 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT SEQUENCE 808 AA: 89775 MW: E3F30E5E334E8E6 CRC64:

Query Match 12.9%; Score 80.5; DB 1; Length 808;
Best Local Similarity 30.8%; Pred. No. 1.8;
Matches 28; Conservative 11; Mismatches 37; Indels 15; Gaps 4;

OY 24 LGSSVALNCTAMVSGPHCSLPYQWLK---DGLPLDIGHYSLHEYSWKANISEVLV 79
Db 260 VGSVDVLLCKKYSDAPH-----IQWLKHVVINGSSFGADGPPYQVQLKTDINISEV-- 312
OY 80 SSVLCGVNTSFEVCAFCISDN---ISSS 107
Db 313 -QVLYLRNVSADAGEYTCLAGNSIGLSYOS 342
```

```
RESULT 6
DSCA_HUMAN STANDARD: PRT: 2012 AA.
AC 060469; 060468;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Down syndrome cell adhesion molecule precursor (CHD2).
DS DSCAM.
GN Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_Taxid=9606;
RN 11
RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
RC TISSUE=Brain;
RX MEDLINE=98087574; PubMed=9426258;
RA Yamakawa K., Huot Y.-K., Haendelt M.A., Hubert R., Chen X.-N.,
RA Lyons G.E., Kornberg J.R.;
RT DSCAM: a novel member of the immunoglobulin superfamily maps in a
RT Down syndrome region and is involved in the development of the
RT nervous system. Mol. Brain Res. 79:118-126(2000).
RN 12
RP SEQUENCE FROM N.A., AND FUNCTION.
RX MEDLINE=20384934; PubMed=10925149;
RA Agarwala K.L., Nakamura S., Tsubumi Y., Yamakawa K.;
RT "Down syndrome cell adhesion molecule DSCAM mediates homophilic
RT intercellular adhesion."
RT Brain Res. Mol. Brain Res. 79:118-126(2000).
RN 13
RP SEQUENCE FROM N.A.
RX MEDLINE=20289799; PubMed=10830953;
RA Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA Park H.-S., Toyoda A., Ishii K., Toroki Y., Choi D.-K., Soda E.,
RA Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A.,
RA Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA Rosenthal A., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Anttonaris S.E.,
RA Minoshima S., Shimizu N., Nordstie G., Horstischer K., Brandt P.,
RA Scharte M., Schoen O., Desario A., Reichelt J., Kauer G., Bloeker H.,
RA Ramer J., Beck A., Klages S., Hennig S., Rieselmann L., Dagand E.,
RA Weinmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA Lehnach H., Reinhardt R., Yaspo M.-L.;
RT "The DNA sequence of human chromosome 21."
RT Nature 405:311-319(2000).
RN 14
RP FUNCTION: CELL ADHESION MOLECULE THAT CAN MEDIATE CATION-
RN INDEPENDENT HOMOPHILIC BINDING ACTIVITY. COULD BE INVOLVED IN
RN NEUROUS SYSTEM DEVELOPMENT.
RN -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN (PROBABLE). THE
RN SHORT ISOFORM MAY BE SECRETED.
RN -1- ALTERNATIVE PRODUCTS: 2 ISOFORMS; A LONG FORM/CHD2-52 (SHOWN HERE)
RN AND A SHORT FORM/CHD2-42; ARE PRODUCED BY ALTERNATIVE SPLICING.
RN -1- TISSUE SPECIFICITY: PRIMARILY EXPRESSED IN BRAIN.
RN -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
RN -1- SIMILARITY: CONTAINS 10 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
RN -1- SIMILARITY: CONTAINS 6 FIBRONECTIN TYPE III-LIKE DOMAINS.
RN -----
RN THIS SWISS-PROT entry is copyright. It is produced through a collaboration
RN between the Swiss Institute of Bioinformatics and the EMBL outstation
RN at the European Bioinformatics Institute. There are no restrictions on its
RN use by non-profit institutions as long as its content is in no way
RN modified and this statement is not removed. Usage by and for commercial
RN entities requires a license agreement (See http://www.isb-sib.ch/announce/
RN or send an email to license@isb-sib.ch).
RN -----
DR EMBL: AF023450; AAC17967.1; -
DR EMBL: AF023449; AAC17966.1; -
DR EMBL: AF217525; AAF27525.1; -
DR EMBL: AL163283; CAB90464.1; -
DR EMBL: AL163282; CAB90436.1; -
DR EMBL: AL163281; CAB90444.1; -
DR EMBL: AL163281; CAB90444.1; -

DR Genew: HGNC:3039; DSCAM.
DR MIM: 602523;
DR InterPro: IPR003961; FN_III.
DR InterPro: IPR003962; FNIII_repeat.
DR InterPro: IPR003006; I9_MHC.
DR InterPro: IPR003598; I9_MHC.
DR InterPro: IPR003600; I9_IIIc.
DR Pfam: PF00041; fn3; 6.
DR Pfam: PF00047; fn3; 10.
DR PRINTS: PR00014; ENTRYPELII.
DR SMART: SM00060; FN3; 6.
DR SMART: SM00410; IG_IIc; 2.
DR SMART: SM00408; IGC2; 7.
DR Immunoglobulin domain; Glycoprotein; Signal; Cell adhesion; Repeat;
KW Transmembrane; Alternative splicing
FT CHAIN 1
FT SIGNAL 1
FT DOMAIN 18 2012
FT TRANSMEM 18 1593
FT DOMAIN 1596 1616
FT DOMAIN 1617 2012
FT DOMAIN 39 109
FT DOMAIN 138 204
FT DOMAIN 239 300
FT DOMAIN 328 392
FT DOMAIN 421 491
FT DOMAIN 491 582
FT DOMAIN 518 676
FT DOMAIN 610 773
FT DOMAIN 704 773
FT DOMAIN 802 872
FT DOMAIN 885 972
FT DOMAIN 984 1076
FT DOMAIN 1088 1177
FT DOMAIN 1189 1273
FT DOMAIN 1300 1366
FT DOMAIN 1380 1463
FT DOMAIN 1477 1562
FT DISULFID 46 102
FT DISULFID 145 197
FT DISULFID 246 293
FT DISULFID 335 385
FT DISULFID 428 484
FT DISULFID 525 575
FT DISULFID 617 669
FT DISULFID 711 766
FT DISULFID 809 859
FT DISULFID 1307 1359
FT CARBOHYD 28 78
FT CARBOHYD 78 28
FT CARBOHYD 470 470
FT CARBOHYD 487 487
FT CARBOHYD 512 512
FT CARBOHYD 556 556
FT CARBOHYD 658 658
FT CARBOHYD 666 666
FT CARBOHYD 710 710
FT CARBOHYD 748 748
FT CARBOHYD 795 795
FT CARBOHYD 924 924
FT CARBOHYD 1142 1142
FT CARBOHYD 1160 1160
FT CARBOHYD 1250 1250
FT CARBOHYD 1271 1271
FT CARBOHYD 1341 1341
FT CARBOHYD 1488 1488
FT CARBOHYD 1562 1562
FT VARSPLIC 1571
FT VARSPLIC 1572
FT VARSPLIC 1893
FT VARSPLIC 2012
FT CONFLICT 1893
FT CONFLICT 2012
SQ SEQUENCE 2012 AA: 222259 MW: 0E33CFB781A0B334 CRC64;
MISSING (IN SHORT ISOFORM).
HRRGDLHPPYRLMDLRRGGRTSRDLSGQACLEPQR
SRTRKPRVPEYIPMEASASSTREGCSMPGAVATLPR
EGATLGOAKWSSQBSLDSRCHLGNPKYASTLV ->
IGVTSYICHTLHEMTTC (IN REF. 1).
NM: 0E33CFB781A0B334 CRC64;
```


Query Match 12.8%; Score 80; DB 1; Length 2012;
Best Local Similarity 26.3%; Pred. No. 5.6;
Matches 26; Conservative 19; Mismatches 38; Indels 16; Gaps 5;

QY 6 DRAPPLSPEDQVLRPALGSSVALNCTAWVSGPHCLSPVQWIKDGLPLIGIHSLSH 65
DB 404 DCTPKIISAFSEKVVSPA--EPVSLMCN---VKG--TLPITITWLDLDDPIKGSRHIS 456
QY 66 ESWVKANSEVLVSSVGVNTSTREYV--GAFCSION 102
DB 457 QMITSEGNVSTYL-----NISSQVRDGVYRCTANN 488

RESULT 7
NPHN_MOUSE
ID NPHN_MOUSE STANDARD; PRT: 1242 AA.
AC 0902S7;
DE 15-JUN-2002 (Rel. 41, Created)
15-JUN-2002 (Rel. 41, Last sequence update)
15-JUN-2002 (Rel. 41, Last annotation update)
DE Nephrit precursor (Renal glomerulus-specific cell adhesion receptor).
GN NPHS1 OR NPHN.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A., AND SUBCELLULAR LOCATION.
RX MEDLINE=99436348; PubMed=10504499;
RA Holman L.B., St John P.L., Kovari I.A., Verma R., Holtzoefer H.,
RA Abrahamson D.R.;
RT "Nephritin localizes to the slit pore of the glomerular epithelial
cell.";
RL Kidney Int. 56:1481-1491(1999).
RN [2]
RP INTERACTION WITH CD2AP.
RX MEDLINE=21590051; PubMed=11733379;
RA Shih N.Y., Li J., Cotran R., Mundel P., Miner J.H., Shaw A.S.;
RT "CDAP localizes to the slit diaphragm and binds to nephritin via a
novel C-terminal domain.";
RL Am. J. Pathol. 159:2303-2308(2001).
RN [3]
RP INTERACTION WITH CD2AP AND NPHS2.
RX MEDLINE=21590460; PubMed=11733557;
RA Schwartz K., Simons M., Reiser J., Saleem M.A., Paul C., Kriz W.,
RA Shaw A.S., Holzman L.B., Mundel P.;
RT "Podocin, a raft-associated component of the glomerular slit
diaphragm, interacts with CD2AP and nephritin.";
RL J. Clin. Invest. 108:1621-1629(2001).
RN [4]
RP FUNCTION: Seems to play a role in the development or function of
the kidney glomerular filtration barrier. May anchor the podocyte
slit diaphragm to the actin cytoskeleton.
CC -1- SUBUNIT: Interacts with podocin/NPHS2 and with CD2AP C-terminal
domain.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein (Potential). Located
at podocyte slit diaphragm between podocyte foot processes.
CC -1- TISSUE SPECIFICITY: Expressed in kidney glomeruli.
CC -1- PTM: Phosphorylated on tyrosine residues (by similarity).
CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
CC -1- SIMILARITY: CONTAINS 8 IMMUNOGLOBULIN-LIKE DOMAINS.
CC -1- SIMILARITY: CONTAINS 1 FIBRONECTIN TYPE III-LIKE DOMAIN.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@sib-sib.ch).
CC -----
CC EMBL: AF168466; AAF03368.1; -
CC MGD: MGI:1859637; Nphs1.
CC InterPro: IPR003961; FN_III.

DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003598; Ig_C2.
DR InterPro: IPR003600; Ig_Like.
DR InterPro: IPR003599; TTP_enzyme.
DR Pfam: PF00041; fn3; 1.
DR Pfam: PF00047; fn3; 8.
DR SMART: SM00060; FN3; 1.
DR SMART: SM00408; FN3; 1.
DR SMART: SM00410; Ig_Like; 3.
KW Cell adhesion; Transmembrane; Signal; Glycoprotein;
KW Immunoglobulin domain; Repeat; Phosphorylation.
FT SIGNAL 1 22
FT CHAIN 23 1242
FT DOMAIN 23 1064
FT TRANSMEM 1065 1086
FT DOMAIN 1087 1242
FT DOMAIN 46 118
FT DOMAIN 153 224
FT DOMAIN 258 324
FT DOMAIN 354 424
FT DOMAIN 458 535
FT DOMAIN 560 630
FT DOMAIN 754 823
FT DOMAIN 856 927
FT DOMAIN 941 1025
FT DISULFID 53 111
FT DISULFID 160 217
FT DISULFID 265 317
FT DISULFID 361 417
FT DISULFID 465 528
FT DISULFID 567 623
FT DISULFID 761 816
FT DISULFID 863 920
FT CARBOHYD 40 40
FT CARBOHYD 356 356
FT CARBOHYD 401 401
FT CARBOHYD 547 547
FT CARBOHYD 553 553
FT CARBOHYD 564 564
FT CARBOHYD 577 577
FT CARBOHYD 680 680
FT CARBOHYD 708 708
FT CARBOHYD 908 908
SQ SEQUENCE 1242 AA; 134890 MW; 02DB2180BF145092 CRC64;

Query Match 12.7%; Score 79.5; DB 1; Length 1242;
Best Local Similarity 29.5%; Pred. No. 3.7;
Matches 26; Conservative 16; Mismatches 29; Indels 17; Gaps 5;

QY 26 SSVALNCTAWVSGPHCLSPVQ--WLKDGVLGI-GGHSLSHSEWVKANSEVLVSSV 82
DB 857 SSATLHCRA-----RGVPNIDFTWTKGVPLDLDPPRYTEHKYH-----QGVVHSSL 903
QY 83 LGV-NVSTREYVGAFTCSIONISFSSET 109
DB 904 LRTIANVSAQDYALFKCTATNALGSDHT 931

RESULT 8
NPHN_RAT
ID NPHN_RAT STANDARD; PRT: 1234 AA.
AC 09R044; 090XHT;
DE 15-JUN-2002 (Rel. 41, Created)
15-JUN-2002 (Rel. 41, Last sequence update)
15-JUN-2002 (Rel. 41, Last annotation update)
DE Nephrit precursor (Renal glomerulus-specific cell adhesion receptor).
GN NPHS1 OR NPHN.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=101116;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).

RT "Genomic structure and complete sequence of the human FGFR4 gene."
 RL Mamm. Genome 9:131-135(1998).
 RN [4]
 RP SEQUENCE OF 609-676 FROM N.A.
 RC TISSUE=Blood;
 RX MEDLINE=91062389; PubMed=2247464;
 RA Patanen J., Maekelae T.P., Altalo R., Lehteslahti H., Altalo K.;
 RT "Putative tyrosine kinases expressed in K-562 human leukemia cells";
 RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
 CC -1- FUNCTION: RECEPTOR FOR ACIDIC FIBROBLAST GROWTH FACTOR. DOES NOT
 CC BIND TO BASIC FIBROBLAST GROWTH FACTOR. BINDS FGFR19.
 CC -1- CATALYTIC ACTIVITY: ATP + a protein tyrosine -> ADP + protein
 CC tyrosine phosphate.
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -1- SIMILARITY: BELONGS TO THE FIBROBLAST GROWTH FACTOR RECEPTOR
 CC FAMILY.
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X57205; CAA04090.1; -;
 DR EMBL; L03840; AAB59389.1; -;
 DR EMBL; Y13901; CAA74200.1; -;
 DR EMBL; M59373; AAA63208.1; -;
 DR PIR; S15345; TVHUF4.
 DR HSSP; P11362; IFGK.
 DR Genew; HGNC:3691; FGFR4.
 DR MIM; 134935; -;
 DR InterPro; IPR000719; Euk_pkinase.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003598; Ig_c2.
 DR InterPro; IPR003600; Ig_Like.
 DR InterPro; IPR002290; Set_thr_pkinase.
 DR InterPro; IPR001245; Tyr_pkinase.
 DR Pfam; PF00047; Ig; 3.
 DR Pfam; PF00069; pkinase; 1.
 DR ProDom; PD000001; Euk_pkinase; 1.
 DR SMART; SM00409; IG; 3.
 DR SMART; SM00410; IG_Like; 2.
 DR SMART; SM00408; IGC2; 3.
 DR SMART; SM00220; S_TKC; 1.
 DR SMART; SM00219; TYRC; 1.
 DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
 DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
 DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
 DR Receptor; Glycoprotein; Tyrosine-protein kinase; ATP-binding;
 KW Transferase; Phosphorylation; Transmembrane; Immunoglobulin domain;
 KW Repeat; Signal.
 FT SIGNAL 1 24 POTENTIAL.
 FT CHAIN 25 802 FIBROBLAST GROWTH FACTOR RECEPTOR 4.
 FT DOMAIN 25 369 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 370 390 POTENTIAL.
 FT DOMAIN 391 802 CYTOPLASMIC (POTENTIAL).
 FT DOMAIN 50 108 IG-LIKE C2-TYPE DOMAIN 1.
 FT DOMAIN 165 231 IG-LIKE C2-TYPE DOMAIN 2.
 FT DOMAIN 264 340 IG-LIKE C2-TYPE DOMAIN 3.
 FT DOMAIN 467 755 PROTEIN KINASE.
 FT NP_BIND 473 481 ATP (BY SIMILARITY).
 FT BINDING 503 503 ATP (BY SIMILARITY).
 FT ACT_SITE 612 612 BY SIMILARITY.
 FT MOD_RES 643 643 PHOSPHORYLATION (AUTO-) (BY SIMILARITY).
 FT DISULFID 57 101 POTENTIAL.
 FT DISULFID 172 224 POTENTIAL.
 FT DISULFID 271 333 POTENTIAL.
 FT CARBOHYD 112 112 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 258 258 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 258 258

FT CARBOHYD 290 290 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 311 311 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 322 322 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CONFLICT 297 297 D -> V (IN REF. 1).
 SQ SEQUENCE 802 AA; 87954 MW; B2B259831B889P CRC64;
 Query Match 12.2%; Score 76.5; DB 1; Length 802;
 Best local similarity 30.8%; Pred. No. 4.5;
 Matches 28; Conservative 10; Mismatches 38; Indels 15; Gaps 4;
 Qy 24 LGSSVALNCTAWVSGPHCSLPYQWLK---DGLPIGIGYSLHEYSWKANLSEVLV 79
 Db 263 VGSIDVELLCKYSDQPH-----IQWLKHIVYSSFGADGPYQVQLKTADINSEV-- 315
 Qy 80 SSVLGVNVTSTFYVGFACFCSION---ISFSS 107
 Db 316 -EVLYLRNVSADGEVYTCLAGNSIGLSVQS 345
 RESULT 10
 MYPF_HUMAN STANDARD; PRT; 1142 AA.
 AC Q14324;
 DT 15-JUL-1999 (Rel. 38, Created)
 DT 15-JUL-1999 (Rel. 38, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Myosin-binding protein C, fast-type (Fast MyBP-C) (C-protein, skeletal
 DE muscle fast-isoform).
 GN MYBPC2 OR MYBPCF.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Fetal skeletal muscle;
 RX MEDLINE=93387319; PubMed=8375400;
 RA Weber F.E., Vaughan K.T., Rejnach F.C., Fischman D.A.;
 RT "Complete sequence of human fast-type and slow-type muscle myosin-
 RT binding-protein C (MyBP-C). Differential expression, conserved domain
 RT structure and chromosome assignment.";
 RL Eur. J. Biochem. 216:661-669(1993).
 CC -1- FUNCTION: THICK FILAMENT-ASSOCIATED PROTEIN LOCATED IN THE
 CC CROSSBRIDGE REGION OF VERTEBRATE STRIATED MUSCLE A BANDS. IN VITRO
 CC IT BINDS MHC, F-ACTIN AND NATIVE THIN FILAMENTS, AND MODIFIES THE
 CC ACTIVITY OF ACTIN-ACTIVED MYOSIN ATPASE. IT MAY MODULATE MUSCLE
 CC CONTRACTION OR MAY PLAY A MORE STRUCTURAL ROLE.
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. MYBP
 CC SUBFAMILY.
 CC -1- SIMILARITY: CONTAINS 7 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
 CC -1- SIMILARITY: CONTAINS 3 FIBRONECTIN TYPE III-LIKE DOMAINS.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X73113; CAA51544.1; -;
 DR HSSP; P56276; ITLK.
 DR Genew; HGNC:7550; MYBPC2.
 DR MIM; 160793; -;
 DR InterPro; IPR003961; FN_III.
 DR InterPro; IPR003962; FNIII_repeat.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003598; Ig_c2.
 DR InterPro; IPR003600; Ig_Like.
 DR Pfam; PF00041; In3; 3.
 DR Pfam; PF00047; Ig; 5.
 DR PRINTS; PR00014; FNTYPEIII.
 DR SMART; SM00060; FN3; 3.

DR SMART: SM00410; IG-like; 6.
DR SMART: SM00408; IGG2; 1.
KW Immunoglobulin domain; Actin-binding; Cell adhesion; Muscle protein;
thick filament; Repeat.
FT DOMAIN 50 153 IG-LIKE C2-TYPE DOMAIN 1.
FT DOMAIN 255 344 IG-LIKE C2-TYPE DOMAIN 2.
FT DOMAIN 345 437 IG-LIKE C2-TYPE DOMAIN 3.
FT DOMAIN 438 539 IG-LIKE C2-TYPE DOMAIN 4.
FT DOMAIN 540 639 IG-LIKE C2-TYPE DOMAIN 5.
FT DOMAIN 640 737 FIBRONECTIN TYPE-III 1.
FT DOMAIN 738 838 FIBRONECTIN TYPE-III 2.
FT DOMAIN 839 933 IG-LIKE C2-TYPE DOMAIN 6.
FT DOMAIN 934 1048 FIBRONECTIN TYPE-III 3.
FT DOMAIN 1049 1142 IG-LIKE C2-TYPE DOMAIN 7.
SQ SEQUENCE 1142 AA; 128142 MW; 93461D435686C09 CRC64;

Query Match 12.2%; Score 76.5; DB 1; Length 1142;
Best Local Similarity 27.8%; Pred No 6.7;
Matches 27; Conservative 13; Mismatches 36; Indels 21; Gaps 5;

8 APPDLSEEDQYLRFALGSSVALNCTAWVSGFHCSPSYQMLKDLPLGIGHYSLHEX 67
1048 APKFLPLIDRVV--VAGYSALNCA--VGHFR--PKVVMKMKREIDPKFLITNY 1100
DB 68 SWARNLSEVLVSSVLGVNTSTEVY--GAFTCISQIN 102
DB 1101 -----OGVLTINIRSPFDAGTYTCRAVN 1125

RESULT 11
NPNH_HUMAN STANDARD; PRT; 1241 AA.
ID NPNH_HUMAN
AC 060500;
DT 15-JUN-2002 (Rel. 41, Created)
DT 15-JUN-2002 (Rel. 41, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Nephlin precursor (Renal glomerulus-specific cell adhesion receptor).
GN NPHS1 OR NPNH.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RE SEQUENCE FROM N.A. (ISOFORM 1).
RA Kestila M., Lehtkeri U., Maenikho M., Lamerdin J., McCreedy P.,
RA Putala H., Ruotsalainen V., Morita T., Nissinen M., Herava R.,
RA Kashtan C.E., Peltonen L., Holmberg C., Olsen A., Tryggvason K.;
RT "Positionally cloned gene for a novel glomerular protein -- nephlin --
is mutated in congenital nephrotic syndrome." Mol. Cell 1:575-582(1998).
RN [2]
RE SEQUENCE FROM N.A. (ISOFORM 1).
RA Grunkemeyer J.A., Kumar N., Kalluri R.;
RT "Human nephlin (NPHS1) cDNA sequence." J.
RL Submitted (SEP-1999) to the EMBL/Genbank/DBJ databases.
RN [3]
RE SEQUENCE OF 1032-1134 FROM N.A. (ISOFORM 2), AND SUBCELLULAR LOCATION.
RX MEDLINE=20019662; PubMed=10550324;
RA Holtlofer H., Ahola H., Solin M.-L., Wang S.-X., Palmén T.,
RA Laitinen P., Miettinen A., Kerjaschki D.;
RT "Nephlin localizes at the podocyte filtration slit area and is
characteristically spliced in the human kidney." J.
RL Am. J. Pathol. 155:1681-1687(1999).
RN [4]
RE SUBCELLULAR LOCATION.
RX MEDLINE=99324171; PubMed=10393930;
RA Ruotsalainen V., Ljungberg P., Wartiovaara J., Lehtkeri U.,
RA Kestila M., Jalanko H., Holmberg C., Tryggvason K.;
RT "Nephlin is specifically located at the slit diaphragm of glomerular
podocytes." J.
KW Proc. Natl. Acad. Sci. U.S.A. 96:7962-7967(1999).
[5]

RP INTERACTION WITH NPHS2.
RX MEDLINE=21551283; PubMed=11562357;
RA Huber T.B., Kotgen M., Schilling B., Walz G., Benzling T.;
RT "Interaction with podocin facilitates nephlin signaling." J.
RL J. Biol. Chem. 276:41543-41546(2001).
RN [6]
RE VARIANTS K-117 AND S-1077, AND VARIANTS CNF S-64, N-171, T-172 DEL;
RP N-173; 205-T-P-R-207 DELINS I; C-270; P-350; R-366; C-367; S-368;
RP V-376; Q-408; Y-465; F-528; Q-610; F-623; C-724; W-802; P-802;
RP D-806; C-831 AND C-1140.
RX MEDLINE=99115081; PubMed=9915943;
RA Lehtkeri U., Maenikho M., McCreedy P., Lamerdin J., Gribouval O.,
RA Naudet P.M., Antignac C.K., Kashtan C.E., Holmberg C., Olsen A.,
RA Kestila M., Tryggvason K.;
RT "Structure of the gene for congenital nephrotic syndrome of the
finnish type (NPHS1) and characterization of mutations." J.
RL Am. J. Hum. Genet. 64:51-61(1999).
RN [7]
RE VARIANTS CNF IYS-447 AND VAL-819.
RX MEDLINE=20117947; PubMed=10652016;
RA Aya K., Tanaka H., Sano Y.;
RT "Novel mutation in the nephlin gene of a Japanese patient with
congenital nephrotic syndrome of the Finnish type." J.
RL Kidney Int. 57:401-404(2000).
CC -1- FUNCTION: Seems to play a role in the development or function of
the kidney glomerular filtration barrier. May anchor the podocyte
terminal domain (by similarity).
CC -1- SUBUNIT: Interacts with podocin/NPHS2. Interacts with CD2AP C-
terminal domain (by similarity).
CC -1- SUBCELLULAR LOCATION: Type I membrane protein (potential).
CC -1- Predominantly located at podocyte slit diaphragm between podocyte
foot processes. Also associated with podocyte apical plasma
membrane.
CC -1- ALTERNATIVE PRODUCTS: 2 isoforms: 1 (shown here) and 2/alpha; are
produced by alternative splicing.
CC -1- TISSUE SPECIFICITY: Specifically expressed in podocytes of kidney
glomeruli.
CC -1- DEVELOPMENTAL STAGE: In 23-week-old embryo found in epithelial
podocytes of the periphery of mature and developing glomeruli.
CC -1- PTM: Phosphorylated on tyrosine residues of developing glomeruli.
CC -1- DISEASE: Defects in NPHS1 are the cause of congenital nephrotic
syndrome of the finnish type (NPHS1 or CNF), an autosomal
recessive disorder characterized by massive proteinuria in utero
and nephrosis at birth.
CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
CC -1- SIMILARITY: CONTAINS 1 FIBRONECTIN TYPE III-LIKE DOMAIN.
CC -1- SIMILARITY: CONTAINS 8 IMMUNOGLOBULIN-LIKE DOMAINS.
CC -1- THIS SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC -----
DR EMBL: AF035835; AAC39687.1; -;
DR EMBL: AF190637; AAC37141.1; -;
DR EMBL: AF126957; AAF36451.1; -;
DR Genew: HGNC:7908; NPHS1.
DR MIM: 602716; -;
DR MIM: 256300; -;
DR InterPro: IPR003961; FN_III.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003598; IG_C2.
DR InterPro: IPR003600; IG_LIKE.
DR Pfam: PF00047; Ig; 8.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00060; FN3; 1.
DR SMART: SM00408; IGG2; 1.
DR SMART: SM00410; IGG2; 1.
DR SMART: SM00410; IG_LIKE; 3.
KW Cell adhesion; Transmembrane; Signal; Glycoprotein;
Immunoglobulin domain; Repeat; Phosphorylation; Alternative splicing;

FT	VARIANT	743	743	R -> C (IN CNF).
FT	VARIANT	802	802	/FtId=VAR_013048.
FT	VARIANT	802	802	R -> W (IN CNF).
FT	VARIANT	802	802	/FtId=VAR_013049.
FT	VARIANT	806	806	R -> P (IN CNF).
FT	VARIANT	806	806	/FtId=VAR_013050.
FT	VARIANT	819	819	A -> D (IN CNF).
FT	VARIANT	819	819	/FtId=VAR_013051.
FT	VARIANT	831	831	D -> V (IN CNF).
FT	VARIANT	831	831	/FtId=VAR_013052.
FT	VARIANT	831	831	R -> C (IN CNF).
FT	VARIANT	831	831	/FtId=VAR_013053.
Query Match		12.2%	Score 76.5; DB 1; Length 1241;	
Best Local Similarity		28.4%	Pred. No. 7.4;	
Matches		29; Conservative	16; Mismatches	34; Indels 23; Gaps 6;
Oy	26	SSVALNCTIAWVSGPHCLPSV--QWLKDGLPLGI-GCHYSLHEYSWVKANLSELYVSSV	82	
Db	857	SSATLHCA-----RCVPNIVFTWNTGNGVPLDLDPRYEHYHOGGVH-----SSL	903	
Oy	83	IGV-NVTSEVYGATCTSIONISFSSFT-----LGRAGPTS	117	
Db	904	LTIANVSAODYALFTCTATNALGSDQTNIOLVSTSRDPPS	945	
RESULT 12				
PGHL_MOUSE				
ID	PGHL_MOUSE	STANDARD:	PRT:	602 AA.
AC	P22437			
DT	01-AUG-1991 (Rel. 19, Created)			
DT	01-AUG-1991 (Rel. 19, Last sequence update)			
DT	15-JUN-2002 (Rel. 41, Last annotation update)			
DE	Prostaglandin G/H synthase 1 precursor (EC 1.14.99.1) (Cyclooxygenase			
DE	-1) (COX-1) (Prostaglandin-endoperoxide synthase 1) (Prostaglandin H2			
DE	synthase 1) (PGH synthase 1) (PGHS-1) (PHS 1).			
GN	PTGS1 OR COX1 OR COX-1.			
OS	Mus musculus (Mouse).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.			
OX	NCBI_TaxID=10090;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RP	MEDLINE=90203007; PubMed=2108169;			
RA	Dewitt D.L., El-Hariri E.A., Kraemer S.A., Andrews M.J., Yao E.F.,			
RA	Armstrong R.L., Smith W.L.;			
RT	"The aspirin and heme-binding sites of ovine and murine prostaglandin			
RT	endoperoxide synthases.";			
RL	J. Biol. Chem. 265:5192-5198(1990).			
CC	-1- FUNCTION: MAY PLAY AN IMPORTANT ROLE IN REGULATING OR PROMOTING			
CC	CELL PROLIFERATION IN SOME NORMAL AND NEOPLASTICALLY TRANSFORMED			
CC	CELLS.			
CC	-1- CATALYTIC ACTIVITY: Arachidonate + AH(2) + 2 O(2) = prostaglandin			
CC	H2 + A + H(2)O.			
CC	-1- PATHWAY: FIRST STEP IN THE FORMATION OF PROSTAGLANDINS AND			
CC	THROMBOXANES.			
CC	-1- SUBUNIT: HOMODIMER.			
CC	-1- SUBCELLULAR LOCATION: Membrane-associated. Microsomal membrane.			
CC	-1- MISCELLANEOUS: THIS ENZYME ACTS BOTH AS A DIOXYGENASE AND AS A			
CC	PEROXIDASE.			
CC	-1- MISCELLANEOUS: THIS ENZYME IS THE TARGET OF NONSTEROIDAL			
CC	ANTI-INFLAMMATORY DRUGS SUCH AS ASPIRIN.			
CC	-1- SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN.			
CC	-1- SIMILARITY: BELONGS TO THE PROSTAGLANDIN G/H SYNTHASE FAMILY.			
CC	-----			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL Outstation -			
CC	the European Bioinformatics Institute. There are no restrictions on its			
CC	use by non-profit institutions as long as its content is in no way			
CC	modified and this statement is not removed. Usage by and for commercial			
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/			
CC	or send an email to license@isb-sib.ch).			
CC	-----			

EMBL: M34141; AAA39913.1; -
DR PIR: A35564; A35564.
DR HSSP: P05979; 1DIY..
DR MGD: MGI:97797; PtgsL.
DR InterPro: IPR002007; Anln_peroxidase.
DR InterPro: IPR00361; EGF-like.
DR Pfam: PF00008; EGF_1.
DR Pfam: PF03098; An_peroxidase; 1.
DR PRINTS: PR00457; ANPEROXIDASE.
DR SMART: SM00181; EGF; 1.
DR PROSITE: PS00022; EGF_1; FALSE_NEG.
DR PROSITE: PS01186; EGF_2; FALSE_NEG.
KW Oxidoreductase; Dioxxygenase; Peroxygenase; Acetylation;
KW Prostaglandin biosynthesis; Heme; Iron; Signal; Membrane;
KW EGF-like domain.
FT SIGNAL 1 26
FT CHAIN 1 26 PROSTAGLANDIN G/H SYNTHASE 1.
FT DOMAIN 27 602 EGF-LIKE.
FT ACT_SITE 34 72 DISTAL HISTIDINE (BY SIMILARITY).
FT ACT_SITE 209 209 CYCLOOXYGENASE (BY SIMILARITY).
FT BINDING 387 387 PROXIMAL HEME LIGAND (BY SIMILARITY).
FT MOD_RES 390 390 ASPIRIN-ACETYLATED SERINE.
FT DISULFID 352 532 BY SIMILARITY.
FT DISULFID 38 49 BY SIMILARITY.
FT DISULFID 43 59 BY SIMILARITY.
FT DISULFID 61 71 BY SIMILARITY.
FT DISULFID 39 77 BY SIMILARITY.
FT CARBOHYD 571 577 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 70 106 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 106 146 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 602 AA; 69042 MW; 634C0E60245C3A0 CRC64;
Query Match 12.1%; Score 76; DB 1; Length 602;
Best Local Similarity 27.4%; Pred. No. 3.6;
Matches 34; Conservative 15; Mismatches 59; Indels 16; Gaps 6;
QY 2 PGVCDRAPDPLSPEDQVLEPRALGSSVAL-----NCTAVVSGPCSLPSV-QMLK 51
DB 22 PSYLLADPGVSPVNPCCYPCQNGCVAFGLDNYQCDCOTRNGSGPNCCTIPEIMTWLR 81
QY 52 DGL-PLGIGGYSL-HEY-SWYKAN---LSEVYSSVLGVNTSTEVGAFCISQIONISE 105
DB 82 NSLRPSSFTFLHTHCYWMLEFVNATFIREVLRVLVYRSRLIRPPTYSANHYISM 141
QY 106 SFT 109
DB 142 ESFS 145
UT 13
ID HUMAN STANDARD; PRT; 822 AA.
AC P11362; P17049;
DT 01-JUL-1989 (Rel. 11, Created)
DT 01-MAY-1991 (Rel. 18, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Basic fibroblast growth factor receptor 1 precursor (BC 2.7.1.112)
DE (EGFR-1) (bFGF-R) (Fms-like tyrosine kinase-2) (c-fgr).
GN FGFR1 OR FLG OR FGFR OR FLR2.
OC Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE-Placenta;
RX MEDLINE-90245600; PubMed-2159626;
RA Isaacchi A., Bergonzoni L., Sarmientos P.;
RT "Complete sequence of a human receptor for acidic and basic
RL fibroblast growth factors.";
RL Nucleic Acids Res. 18:1906-1906(1990).
RN [2]
RP SEQUENCE FROM N.A.

RC TISSUE-Neonatal brain stem;
RX MEDLINE-90360977; PubMed-1697263;
RA Dionne C.A., Crumley G.R., Ballot F., Kaplow J.M., Searfoss G.,
RA Ruta M., Burgess W.H., Jaye M., Schlessinger J.,
RT "Cloning and expression of two distinct high-affinity receptors
RT cross-reacting with acidic and basic fibroblast growth factors.";
RL EMBO J. 9:2685-2692(1990).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE-92282615; PubMed-1317750;
RA Hattori Y., Odagiri H., Katoh O., Sakamoto H., Morita T.,
RA Shimocho K., Tobinai K., Sugimura T., Terada M.;
RT "K-sam-related gene, N-sam, encodes fibroblast growth factor receptor
RT and is expressed in T-lymphocytic tumors.";
RL Cancer Res. 52:3367-3371(1992).
RN [4]
RP SEQUENCE FROM N.A.
RC TISSUE-Liver;
RX MEDLINE-91126480; PubMed-1846977;
RA Hou J., Kan M., McKeenan K., McBride G., Adams P., McKeenan W.L.;
RT "Fibroblast growth factor receptors from liver vary in three
RT structural domains.";
RL Science 251:665-668(1991).
RN [5]
RP SEQUENCE FROM N.A.
RX MEDLINE-92118399; PubMed-1662973;
RA Kiefer M.C., Baird A., George-Nascimento C., Nguyen T., Mason O.B.,
RA Boley L.D., Valenzuela P., Barr P.J.;
RT "Molecular cloning of a human basic fibroblast growth factor receptor
RT cDNA and expression of a biologically active extracellular domain in
RT a baculovirus system.";
RL Growth factors 5:115-127(1991).
RN [6]
RP SEQUENCE FROM N.A.
RC TISSUE-Placenta;
RX MEDLINE-90290512; PubMed-2162671;
RA Itoh N., Terachi T., Ohta M., Seo M.K.;
RT "The complete amino acid sequence of the shorter form of human basic
RT fibroblast growth factor receptor deduced from its cDNA.";
RL Biochem. Biophys. Res. Commun. 169:680-685(1990).
RN [7]
RP SEQUENCE OF 201-822 FROM N.A.
RA Ruta M., Hawk R., Ricca G., Drohan W., Zabejshansky M., Laureys G.,
RA Barton D.E., Francke U., Schlessinger J., Givol D.;
RT "A novel protein tyrosine kinase gene whose expression is modulated
RT during endothelial cell differentiation.";
RL Oncogene 3:9-15(1988).
RN [8]
RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
RX MEDLINE-90355989; PubMed-2167437;
RA Johnson D.E., Lee P.L., Lu J., Williams L.T.;
RT "Diverse forms of a receptor for acidic and basic fibroblast growth
RT factors.";
RL Mol. Cell. Biol. 10:4728-4736(1990).
RN [9]
RP ALTERNATIVE SPLICING.
RX MEDLINE-91141499; PubMed-1847500;
RA Gutkind S.J., Link D.C., Katamine S., Lacal P., Miki T., Ley T.J.,
RA Robbins K.C.;
RT "A novel c-fgr exon utilized in Epstein-Barr virus-infected B
RT lymphocytes but not in normal monocytes.";
RL Mol. Cell. Biol. 11:1500-1507(1991).
RN [10]
RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
RC TISSUE-Lung;
RX MEDLINE-91319400; PubMed-1650441;
RA Eisenmann A., Ahn J.A., Graziani G., Tronick S.R., Ron D.;
RT "Alternative splicing generates at least five different isoforms of
RL the human basic-FGF receptor.";
RN [11]
RP SEQUENCE FROM N.A.
RC Wennstroem S., Sandstroem C., Claesson-Welsh L.;

Submitted (JUL-1990) to the EMBL/Genbank/DBJ databases.

RL [12] MUTAGENESIS OF TYR-766.
 RN MEDLINE-92357144; PubMed-1379697;
 RX Peters K.G., Marie J., Wilson E., Ives H.E., Escobedo J.,
 RA del Rosario M., Mirda D., Williams L.T.;
 RT "Point mutation of an FGF receptor abolishes phosphatidylinositol
 turnover and Ca²⁺ flux but not mitogenesis.";
 RL Nature 358:678-681(1992).

RL [13] MUTAGENESIS OF TYR-766.
 RN MEDLINE-92357145; PubMed-1379698;
 RX Mohammad M., Dionne C.A., Li W., Lin N., Spivak T., Honegger A.M.,
 RA Jave M., Schlessinger J.;
 RT "Point mutation in FGF receptor eliminates phosphatidylinositol
 hydrolysis without affecting mitogenesis.";
 RL Nature 358:681-684(1992).

RL [14] X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 464-762.
 RN MEDLINE-96361355; PubMed-8752212;
 RA Mohammad M., Schlessinger J., Hubbard S.R.;
 RT "Structure of the FGF receptor tyrosine kinase domain reveals a novel
 autoinhibitory mechanism.";
 RL Cell 86:577-587(1996).

RL [15] X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 464-762.
 RN MEDLINE-97284786; PubMed-9139660;
 RX Mohammad M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K.,
 RA Hubbard S.R., Schlessinger J.;
 RT "Structures of the tyrosine kinase domain of fibroblast growth factor
 receptor in complex with inhibitors.";
 RL Science 276:955-960(1997).

RL [16] VARIANT PEIFFER SYNDROME ARG-252.
 RN MEDLINE-95179173; PubMed-7874169;
 RA Mueller M., Scheil U., Hehr A., Robin N.R., Losken H.W., Schinzel A.,
 RA Puelley L.J., Rutland P., Reardon W., Malcolm S., Winter R.M.;
 RT "A common mutation in the fibroblast growth factor receptor 1 gene in
 Pfeiffer syndrome.";
 RL Nat. Genet. 8:269-274(1994).

CC -1 FUNCTION: RECEPTOR FOR BASIC FIBROBLAST GROWTH FACTOR. A SHORTER
 CC FORM OF THE RECEPTOR COULD BE A RECEPTOR FOR ACIDIC FGF (AFGF).
 CC -1 CATALYTIC ACTIVITY: ATP + a protein tyrosine = ADP + protein
 CC tyrosine phosphate.
 CC -1 SUBCELLULAR LOCATION: Type I membrane protein.
 CC -1 ALTERNATIVE PRODUCTS: MANY FORMS OF FGFR1 ARE PRODUCED BY
 CC ALTERNATIVE SPLICING. THE FORM SHOWN HERE IS KNOWN AS ALPHA-A1.
 CC -1 DISEASE: DEFECTS IN FGFR1 ARE ONE OF THE CAUSES OF PEIFFER
 CC SYNDROME (FS) (ALSO KNOWN AS ACROCEPHALOSYNDACTYL TYPE V; ACSS);
 CC CHARACTERIZED BY CRANIOSYNOSTOSIS (PREMATURE FUSION OF THE SKULL
 CC SUTURES) WITH DEVIATION AND ENLARGEMENT OF THE THUMBS AND GREAT
 CC TOES, BRACHYMESEPHALANGY, WITH PHALANGAL ANKYLOSIS AND A VARYING
 CC DEGREE OF SOFT TISSUE SYNDACTYL.
 CC -1 DISEASE: Involved in a t(8;13)(p12;q12) chromosomal translocation
 CC which involves FGFR1 AND ZNF198. The resulting transcript is a
 CC possible candidate for stem cell leukemia lymphoma syndrome/SCLL.
 CC -1 SIMILARITY: BELONGS TO THE FIBROBLAST GROWTH FACTOR RECEPTOR
 CC FAMILY.
 CC -1 SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
 CC -1 DATABASE: NAME-Atlas Genet. Cytogenet. Oncol. Haematol.;
 CC WWW="http://www.infobiogen.fr/services/chromcancer/Genes/FGFR1113.html".

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@sib.ch).

CC EMBL; X51803; CAA36101.1; -
 CC EMBL; X52833; CAA37015.1; -
 CC EMBL; X66945; CAA47375.1; -
 DR

DR EMBL; Y00665; CAA68679.1; -
 DR EMBL; M37722; AAA75007.1; -
 DR EMBL; M60485; AAA35840.1; -
 DR EMBL; M63887; AAA35958.1; -
 DR EMBL; M34185; AAA35836.1; -
 DR EMBL; M34186; AAA35837.1; -
 DR EMBL; X57118; CAA40400.1; ALT_TERM.
 DR EMBL; X57119; CAA40401.1; -
 DR EMBL; X57120; CAA40402.1; -
 DR EMBL; X57121; CAA40403.1; -
 DR EMBL; X57122; CAA40404.1; -
 DR EMBL; M34641; AAA35835.1; -
 DR EMBL; A29216; CAA01958.1; -
 DR PIR; S11692; TVHUNG.
 DR PIR; S25420; S25420.
 DR PIR; S26739; S26739.
 DR PDB; 1FGK; 23-JUL-97.
 DR PDB; 1FGI; 08-APR-98.
 DR PDB; 1AGW; 25-MAR-98.
 DR Genew; HGNC:3688; FGFR1.
 DR MIM; 136350; -
 DR MIM; 101600; -
 DR InterPro; IPR000719; Euk_pkinase.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003598; Ig_C2.
 DR InterPro; IPR001245; Tyr_pkinase.
 DR Pfam; PF00047; Ig_3.
 DR Pfam; PF00069; pkinase; 1.
 DR PRINTS; PR00109; TYRKINASE.
 DR Prodom; PD000001; Euk_pkinase; 1.
 DR SMART; SM00408; IGC2; 3.
 DR SMART; SM00219; TYRK; 1.

Query Match 12.1%; Score 75.5; DB 1; Length 822;
 Best Local Similarity 31.3%; Pred. No. 5.8;
 Matches 26; Conservative 9; Mismatches 31; Indels 17; Gaps 4;

OY 23 ALGSSVALNCTAMVYSGPRHSPVQWMLKDGLPLGIGHSLSHEYSWVANKSEVLYSSV 82
 DB 268 ALGSNVEFMCK--VYSDPQ--PHIQWLK-----HIEVNGSKRGPDNPYQVILRT 313
 OY 83 LGVNTSTVEYGAFTCSIONISF 105
 DB 314 AGVNTTDKEME--VLHKNVSF 333

RESULT 14
 ID FGFR1_MOUSE STANDARD; PRT; 822 AA.
 AC P16092; Q01736; Q61562;
 DT 01-APR-1990 (Rel. 14, Created)
 DT 01-MAY-1991 (Rel. 18, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Basic fibroblast growth factor receptor 1 precursor (BC 2.7.1.112)
 GN FGFR1 OR FIG.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Brain;
 RX MEDLINE-90160373; PubMed-1689490;
 RA Reid H.H., Wilks A.F., Bernard O.;
 RT "Two forms of the basic fibroblast growth factor receptor-like mRNA
 RT are expressed in the developing mouse brain.";
 RL Proc. Natl. Acad. Sci. U.S.A. 87:1596-1600(1990).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=BA1B/C; TISSUE=Brain;
 RX MEDLINE-90265603; PubMed-2161096;
 RA Safra A., Avivi A., Orr-Urtreger A., Neufeld G., Lomai P.,

THIS PAGE BLANK (USPTO)

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 14, 2002, 17:27:23 : Search time 33 Seconds

(without alignments)
736.775 Million cell updates/sec

Title: US-09-598-443-2_COPY_1_118

Sequence: 1 MPGVCDRAFPFLSPEDQVL.....SIGNISPSFTLQACPTSH 118

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Number of hits satisfying chosen parameters: 671580

Total number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL_21:*

- 1: sp.archaea:*
- 2: sp.bacteria:*
- 3: sp.fungi:*
- 4: sp.human:*
- 5: sp.invertebrate:*
- 6: sp.mammal:*
- 7: sp.mhc:*
- 8: sp.organelle:*
- 9: sp.phage:*
- 10: sp.plant:*
- 11: sp.protist:*
- 12: sp.virus:*
- 13: sp.verticillate:*
- 14: sp.unclassified:*
- 15: sp.virus:*
- 16: sp.bacteriap:*
- 17: sp.archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Length	DB	ID	Description
1	626	100.0	410	4	Q9H733	Q9H733 homo sapien
2	407.5	65.1	409	11	Q9JL28	Q9JL28 mus musculu
3	105	16.8	1319	4	Q9HCD3	Q9HCD3 homo sapien
4	96	15.3	534	5	Q9VSG5	Q9VSG5 drosophila
5	94.5	15.1	295	5	Q9VSG29	Q9VSG29 drosophila
6	94	15.0	793	11	Q70246	Q70246 mus musculu
7	93.5	14.9	7962	4	Q10465	Q10465 homo sapien
8	93.5	14.9	34350	4	Q8W242	Q8W242 homo sapien
9	91.5	14.6	1323	13	Q08476	Q08476 gallus gall
10	90	14.4	6620	4	Q96AA2	Q96AA2 homo sapien
11	90	14.4	6831	5	Q23550	Q23550 caenorhabdi
12	90	14.4	7160	5	Q23551	Q23551 caenorhabdi
13	88	14.1	1036	5	Q8SWM3	Q8SWM3 drosophila
14	88	14.1	1336	5	Q9VNI4	Q9VNI4 drosophila
15	88	14.1	2673	4	Q96SC3	Q96SC3 homo sapien
16	88	14.1	5636	4	Q96RM7	Q96RM7 homo sapien

17	87.5	14.0	5198	5	Q76518	Q76518 caenorhabdi
18	84	13.4	298	4	Q96HT1	Q96HT1 homo sapien
19	84	13.4	836	4	Q94856	Q94856 homo sapien
20	84	13.4	1174	11	Q91260	Q91260 rattus norv
21	84	13.4	2053	4	Q8WU7	Q8WU7 homo sapien
22	84	13.4	2113	4	Q8TD84	Q8TD84 homo sapien
23	82.5	13.2	500	5	Q9XZ87	Q9XZ87 drosophila
24	82.5	13.2	4824	5	Q95YM1	Q95YM1 procambarus
25	82.5	13.2	17352	5	Q95YM2	Q95YM2 procambarus
26	82	13.1	582	11	Q8R4B5	Q8R4B5 mus musculu
27	82	13.1	915	11	Q8R4B3	Q8R4B3 mus musculu
28	81.5	13.0	496	5	Q9W260	Q9W260 drosophila
29	81.5	13.0	500	5	Q961W0	Q961W0 drosophila
30	81.5	13.0	650	11	Q63709	Q63709 rattus rat
31	81.5	13.0	1419	13	Q98SM3	Q98SM3 brachydanio
32	81	12.9	1151	11	Q9QVW5	Q9QVW5 rattus sp.
33	81	12.9	1217	11	P97685	P97685 rattus norv
34	80.5	12.9	6875	6	Q28733	Q28733 oryctolagus
35	80	12.8	1746	4	Q8WY19	Q8WY19 homo sapien
36	80	12.8	4650	4	Q15598	Q15598 homo sapien
37	80	12.8	6632	5	Q17362	Q17362 caenorhabdi
38	80	12.8	6632	5	Q01761	Q01761 caenorhabdi
39	80	12.8	26926	4	Q10466	Q10466 homo sapien
40	80	12.8	26926	4	Q8WZB3	Q8WZB3 homo sapien
41	79.5	12.7	137	13	Q9YHS0	Q9YHS0 ginglymosto
42	79.5	12.7	868	11	Q62838	Q62838 rattus norv
43	79.5	12.7	1256	11	Q9ET59	Q9ET59 mus musculu
44	79.5	12.7	1256	11	Q9J1X1	Q9J1X1 mus musculu
45	79.5	12.7	1256	11	Q92555	Q92555 mus musculu

ALIGNMENTS

Q9H733	PRELIMINARY:	PRT:	410 AA.
ID	Q9H733		
AC	Q9H733:		
DT	01-MAR-2001 (TREMBLrel. 16, Created)		
DR	01-MAR-2001 (TREMBLrel. 16, Last sequence update)		
DE	01-JUN-2002 (TREMBLrel. 21, Last annotation update)		
CD	CDNA: FLJ21446 f1s, clone COL04458.		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Euteria; Primates; Catarrhini; Hominiidae; Homo.		
OX	NCBI_TaxID=9606;		
RM	[1]		
RP	SEQUENCE FROM N.A.		
RC	TISSUE-COLON:		
RA	Kawabata A., Hiki J. T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,		
RA	Okutani R., Ota T., Suzuki Y., Odayashi M., Nishi T., Shibahara T.,		
RA	Tanaka T., Nakamura Y., Isogai T., Sugano S.,		
RT	"NEBO human cDNA sequencing project."		
RL	Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.		
DR	EMBL: AK025099; BAB15066.1; -		
DR	InterPro: IPR003600; IG_Like.		
DR	InterPro: IPR000157; TIR_domain.		
DR	Pfam: PF01582; TIR; 1.		
DR	PRINTS: PR01559; DUFFYANTIGEN.		
DR	SMART: SM00410; IG_Like; 1.		
DR	SMART: SM00255; TIR; 1.		
SO	SEQUENCE 410 AA: 45707 MW: 2A7A663D79567ED6 CRC64:		
Query Match	100.0%; Score 626; DB 4; Length 410;		
Best Local Similarity	100.0%; Pred. No. 6e-60;		
Matches 118; Conservative	0; Mismatches 0; Indels 0; Gaps 0;		
QY	1 MPGVCDRAFPFLSPEDQVLRLPALGSSVALNTAVVSGPHCSLPSVQMLKGLGIGG 60		
DB	1 MPGVCDRAFPFLSPEDQVLRLPALGSSVALNTAVVSGPHCSLPSVQMLKGLGIGG 60		
QY	61 HSLHLEYSVWKANLSEVLVSSVLGVNVTSTEVYGAFTCSIGNISPSFTLQACPTSH 118		

RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA Palazolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Rehert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA Shue B.C., Siden-Klimas I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Svirska R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.,
RT "The genome sequence of *Drosophila melanogaster*."
RL Science 287:2185-2195(2000).
DR EMBL: AE003556; AAF50456.1; -
DR Flybase: FBgn0035863; CG18650.
DR InterPro: IPR003598; Ig_C2.
DR InterPro: IPR003006; Ig_MHC.
DR Pfam: PF00047; Ig; 6.
DR SMART: SM00408; IGC2; 4.
KW Immunoglobulin domain.
SQ SEQUENCE 534 AA; 59845 MW; E22071BAE89D2F66 CRC64;

Query Match 15.3%; Score 96; DB 5; Length 534;
Best local similarity 29.6%; Pred. No. 0.055;
Matches 29; Conservative 17; Mismatches 38; Indels 14; Gaps 5;

QY 6 DRAPDLSPSEDQVLRPALGSSVALNCTAWVSGPHCSLP-SYOMLKDGLPLGIGYSLH 65
DB 156 DASPELLYMFSEQTLP--GPVSLKCYA--TGNP---LPQFWMSLDGFPIDPSRPLVG 208
QY 66 EYSWVAVN-LSEVLVSSVLCVNTSTEVYGAFTCSION 102
DB 209 QYVTHDVISHVINSV-----KEEDGGEYCTAON 240

RESULT 5
Q9YS29 PRELIMINARY; PRT; 295 AA.
AC Q9YS29; 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-DEC-2001 (Tremblrel. 19, Last annotation update)
DE CG8618 protein.
GN CG8618.
OC Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-BERKELEY;
RX MEDLINE=20196006; PubMed=10731132;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Mortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.-H.C., Blazer J.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Mitros G.L.G.,
RA Abril J.F., Agbayani A., An H.-J., Andrews-Frankoch C., Baldwin D.,
RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu U., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandal D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotlier P.,
RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
RA Foster C., Gabrielian A.E., Gary N.S., Gelbart W.M., Glasser K.,
RA Glodok A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Helman T.J., Hernandez J.R., Houck J.,

RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA Jafali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Kethum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Lasro P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Maitel B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA Palazolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Rehert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA Shue B.C., Siden-Klimas I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Svirska R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.,
RT "The genome sequence of *Drosophila melanogaster*."
RL Science 287:2185-2195(2000).
DR EMBL: AE003560; AAF50601.1; -
DR Flybase: FBgn0035748; CG8618.
DR InterPro: IPR003598; Ig_C2.
DR InterPro: IPR003006; Ig_MHC.
DR Pfam: PF00047; Ig; 4.
DR SMART: SM00408; IGC2; 2.
KW Immunoglobulin domain.
SQ SEQUENCE 295 AA; 48F455CE162C4FE1 CRC64;

Query Match 15.1%; Score 94.5; DB 5; Length 295;
Best local similarity 28.2%; Pred. No. 0.038;
Matches 29; Conservative 20; Mismatches 39; Indels 15; Gaps 5;

QY 1 MGCVCRAPDELSPSEDQVLRPALGSSVALNCTAWVSGPHCSLP-SYOMLKDGLPLGIG 59
DB 91 LPDDIRQLPRLKPLSPFQNTIQLNMGRASLTCS--VKG---DLPLTIWKRKGRIIDPT 145
QY 60 GHYSIHYSWVKNLSEVLVSSVLCVNTSTEVYGAFTCSION 102
DB 146 QHMSVKQVD---QYNSILVLENLGSDDT---GMYSCVVRN 179

RESULT 6
Q70246 PRELIMINARY; PRT; 793 AA.
AC Q70246; 01-AUG-1998 (Tremblrel. 07, Created)
DT 01-AUG-1998 (Tremblrel. 07, Last sequence update)
DT 01-DEC-2001 (Tremblrel. 19, Last annotation update)
DE Putative neuronal cell adhesion molecule (PUNC) (Putative neuronal
cell adhesion molecule, short form).
GN PUNC.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-SWISS WEBSTER;
RX MEDLINE=98175891; PubMed=9507132;
RA Salbaum J.M.;
RT "Punc, a novel mouse gene of the immunoglobulin superfamily, is
expressed predominantly in the developing nervous system.";
RT Mech. Dev. 71:201-204(1998).
RN [2]
RP SEQUENCE OF 599-715 FROM N.A.
RC STRAIN-FVB;
RX MEDLINE=99122837; PubMed=9922388;
RA Salbaum J.M.;
RT "Genomic structure and chromosomal localization of the mouse gene
Punc.";
RL Mamm. Genome 10:107-111(1999).
DR EMBL: AF026465; AAD12133.1; -

DR EMBL: AF026466; AAD12124.1; -
 DR HSSP: P80362; 1MTL.
 DR MGD: MG1:1202390; Punc.
 DR InterPro: IPR003961; FN_III.
 DR InterPro: IPR003598; IG_C2.
 DR InterPro: IPR003006; IG_MHC.
 DR Pfam: PF00041; fn3; 2.
 DR Pfam: PF00047; 19; 4.
 DR SMART: SM00060; FN3; 2.
 DR SMART: SM00408; IG_C2; 4.
 DR Immunoglobulin domain.
 DR SEQUENCE 793 AA; 84287 MW; 65FD4D1D5E952937 CRC64;
 Query Match 15.0%; Score 94; DB 11; Length 793;
 Best Local Similarity 30.7%; Pred. No. 0.15;
 Matches 31; Conservative 11; Mismatches 41; Indels 18; Gaps 4;
 QY 7 RAPDFLSPEDQVLRPALGSSVALNCTAWVSGPHCSLPVOMLKDGLPLGIGHYSLHE 66
 DB 339 QAVAEVYHPOSISRPA-GTAMFTQAGQEPPEH-----VTMLKNGVLAGGHVRL-- 390
 DB 67 YSWKALSEVLYSVLVGVNTSTEVYGAFTCSIONISFS 107
 DB 391 ----KNN-----NSTLSTSGVGPEDALYQCAENIAGSS 421

RESULT 7
 ID 010465 PRELIMINARY; PRT; 7962 AA.
 DC 01-MAR-2002 (TREMBLrel. 01, Created)
 DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
 DT 01-JUN-2002 (TREMBLrel. 21, Last annotation update)
 DE Titin, skeletal muscle isoform (EC 2.7.1.1-) (Connectin) (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 NCBI_Taxid=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE-SKELETAL MUSCLE.
 RX MEDLINE=96026330; PubMed=7569978;
 RA Labett S., Kolmer B.,
 RA "titin: giant proteins in charge of muscle ultrastructure and
 RT elasticity".
 RT Science 270:293-296(1995).
 CC -1- FUNCTION: THIS GIANT MUSCLE PROTEIN MAY BE INVOLVED IN MUSCLE
 CC ASSEMBLY AND IN MAINTAINING THE STRUCTURAL INTEGRITY OF
 CC SARCOMERES. MAY HAVE PROTEIN KINASE ACTIVITY.
 CC -1- ALTERNATIVE PRODUCTS: A NUMBER OF FORMS OF THIS PROTEIN ARE
 CC PRODUCED BY ALTERNATIVE SPLICING WHICH DIFFER IN TISSUE
 CC DISTRIBUTION. DIFFERENT SIZE TRANSCRIPTS MAY ALSO EXIST WITHIN ANY
 CC ONE TISSUE.
 CC -1- TISSUE SPECIFICITY: MUSCLE-SPECIFIC.
 CC -1- SIMILARITY: TO THE CATALYTIC DOMAINS OF OTHER SERINE/THREONINE
 CC KINASES.
 CC -1- SIMILARITY: BELONGS TO IMMUNOGLOBULIN SUPERFAMILY. CONTAINS 90
 CC EMBL: X90569; CAA62189.1; -
 DR HSSP: P56276; 1TLK
 DR InterPro: IPR003598; IG_C2.
 DR InterPro: IPR003600; IG_III.
 DR InterPro: IPR003006; IG_MHC.
 DR InterPro: IPR004168; PPAK_molif.
 DR Pfam: PF00047; 19; 59.
 DR Pfam: PF02818; PPAK; 53.
 DR SMART: SM00060; FN3; 2.
 DR SMART: SM00410; IG_III; 15.
 DR Muscle protein: Cytoskeleton: Structural protein; Phosphorylation;
 DR Serine/threonine-protein kinase; Alternative splicing; Repeat;
 DR Immunoglobulin domain.
 FT NON_TER 1
 DOMAIN 5618 7792 GLU/LYS/PRO/VAL-RICH.

FT NON_TER 7962 7962
 SQ SEQUENCE 7962 AA; 883018 MW; B8524053CBAD58 CRC64;
 Query Match 14.9%; Score 93.5; DB 4; Length 7962;
 Best Local Similarity 32.8%; Pred. No. 2.8;
 Matches 38; Conservative 7; Mismatches 32; Indels 39; Gaps 7;
 QY 10 DFLSPEDQVLR-----PALGSSVALNCTAWVSGPHCSLP-SVQRL 50
 DB 1883 DFGSSCDAYLRVLDQNPSPFTKKLRKMKXVIGSSIHNMCK---VSG---SLPISQNF 1936
 QY 51 KDGLPLGIGHYSL--HEYSWKALSEVLYSVLVGVNTSTEVYGAFTCSIONIS 104
 DB 1937 KDGKEISYSAKRYLVCHERS-----VS--LEVNNLELDITANYICKVSNVA 1980

RESULT 8
 ID 08WZ42 PRELIMINARY; PRT; 34350 AA.
 AC 08WZ42;
 DT 01-MAR-2002 (TREMBLrel. 20, Created)
 DT 01-MAR-2002 (TREMBLrel. 20, Last sequence update)
 DT 01-JUN-2002 (TREMBLrel. 21, Last annotation update)
 DE Titin.
 GN TNF.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 NCBI_Taxid=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20309627; PubMed=10850961;
 RA Freiburg A., Tromblitas K., Hell W., Cazorla O., Fougereuse F.,
 RA Center T., Kolmerer B., Wilt C., Beckmann J.S., Gregorio C.C.,
 RA Granzier H., Labett S.;
 RT "series of exon-skipping events in the elastic spring region of titin
 RT as the structural basis for myofibrillar elastic diversity".
 RT Circ. Res. 86:1114-1121(2000).
 RL [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21573839; PubMed=11717165;
 RA Bang M.L., Centner T., Fornoff F., Geach A.J., Gotthardt M.,
 RA McNabb M., Wilt C.C., Labett D., Gregorio C.C., Granzier H.,
 RA Labett S.;
 RT "The complete gene sequence of titin, expression of an unusual ~700
 RT kDa titin isoform and its interaction with obscurin identify a novel
 RT z-line to i-band linking system".
 RL Circ. Res. 89:1065-1072(2001).
 DR EMBL: AJ277892; CAD12456.1; -
 DR InterPro: IPR000282; CytoK_receptor_2.
 DR InterPro: IPR000719; Euk_pkinase.
 DR InterPro: IPR000577; FGCV_kin.
 DR InterPro: IPR003961; FN_III.
 DR InterPro: IPR001092; HLM_basic.
 DR InterPro: IPR003598; IG_C2.
 DR InterPro: IPR003006; IG_MHC.
 DR InterPro: IPR003596; IG_V.
 DR InterPro: IPR002016; Peroxidase.
 DR InterPro: IPR004168; PPAK_molif.
 DR InterPro: IPR002290; Ser_thr_kinase.
 DR InterPro: IPR001245; Tyr_kinase.
 DR Pfam: PF00041; fn3; 132.
 DR Pfam: PF00047; 19; 146.
 DR Pfam: PF00069; pkinase; 1.
 DR Pfam: PF02818; PPAK; 53.
 DR ProDom: PD000001; Euk_pkinase; 1.
 DR SMART: SM00060; FN3; 133.
 DR SMART: SM00409; IG; 167.
 DR SMART: SM00408; IG_C2; 148.
 DR SMART: SM00406; TGV; 23.
 DR SMART: SM00220; S_TG; 1.
 DR SMART: SM00219; TYRCK; 1.

DR PROSITE: PS00933; EGGY_KINASES_1; UNKNOWN_1.
DR PROSITE: PS00038; HELIX_LOOP_HELIX; UNKNOWN_1.
DR PROSITE: PS00280; IG_MHC; UNKNOWN_1.
DR PROSITE: PS00435; PEROXINASE_1; UNKNOWN_1.
DR PROSITE: PS00011; PROTEIN_KINASE_DOM; 1.
DR PROSITE: PS00109; PROTEIN_KINASE_TYR; UNKNOWN_1.
SQ SEQUENCE 34350 AA; 5b1120058a77c558a CRC64;

Query Match	14.98;	Score	93.5;	DB	4;	Length	34350;
Best Local Similarity	32.88;	Pred. No.	17;				
Matches	38;	Conservative	7;	Mismatches	32;	Indels	39;
						Gaps	7;

```

QY 10 DLSPSEQVLR-----PALGSSVALNCIAWVSGPHCSLP-SVQWL 50
    ||| ||| ||| : ||| ||| ||| ||| |||
DB 6145 DCGSSSCCAYLRLVLDQNPSPFTKLTAKMDKVLGSSLIHMECK--VSG--SLPISAQWF 6198

```

0Y 51 KDGLPICIGHYSL--HEYSWKANLSEYLVSSVLGNVSTVEYGAFTCSIONIS 104
||| : ||| ||| ||| :||| :||:
6199 KDGKEIESTA KYRLVCHERS-----VS--LEVNANLELEDTANYTCKKSNVA 6242

RESULT 9
Q08476
ID Q08476 PRELIMINARY; PRT; 1323 AA.

DT 01-NOV-1996 (TREMBLREL. 01, Created)
 DT 01-NOV-1996 (TREMBLREL. 01, Last sequence update)
 DT 01-DEC-2001 (TREMBLREL. 19, Last annotation update)
 DE connectn(tlftio) (Fragment).
 OS Gallus gallus (Chicken).
 OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neornathae; Galliformes; Phasianidae; Phasianinae;
 OC Gallus.
 NCBI_TaxID=9031;

RP SEQUENCE FROM N.A.
RC TISSUE-SKELETAL MUSCLE;
RA Maruyama K., Endo T., Kume H., Kawamura Y., Kanzawa N., Nakauchi Y.,
R Kimura S., Kawashima S., Maruyama K.;
RT "A novel domain sequence of connectin localized at the I band of
RT skeletal muscle sarcomeres: homology to neurofilament subunits.",
RL Cell. Mol. Biol. Res. 194:1286-1291(1993).
DR EMBL; D16541; BAA0379.1; -;
DR HSSP; P56276; ITLK.
DR InterPro: IPR003598; Ig-c2.
DR InterPro: IPR003600; Ig_1like.
DR InterPro: IPR003006; Ig_MHC.
Pfam: PF00047; Ig; 11.
SMART: SM00408; Igc2; 9.
SMART: SM00410; Igc_1like; 2.
DR Immunoglobulin domain.
KW NON_TER 1
FT NON_TER 1
SQ SEQUENCE 1323 AA; 148581 MW; 3974F640820CA926B CRC64;

Query Match	14.68;	Score 91.5;	DB 13;	Length 1323;
Best Local Similarity	24.58;	Pred. No. 0.51;		
Matches 27; Conservative	21;	Mismatches	31;	Indels 31; Gaps 5

```
OY      66 EYSWKNANLSEVLSSYLGVNNTSTEVYGAFICIONISFSSFTLQRACP 115
DB      1009 --TQVSDRKHLLIKDV-----RTDQOAYTKCDLNLETTADLTLEAP 1050
```

RESULT	10	
Q96AA2		
Q96AA2	PRELIMINARY;	PRT; 6620 AA.
AC	Q96AA2	
DT	01-DEC-2001	(TREMBLERel. 19, Created)
DT	01-DEC-2001	(TREMBLERel. 19, Last sequence update)

DT 01-JUN-2002 (TREMBLREL. 21, Last annotation update)
DE Obscurin.
GN OBSCN.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
NX NCBI_TaxID=9606;

RP SEQUENCE FROM N.A.
RC TISSUE=HEART;
RX MEDLINE=21342081; PubMed=11448995;

RT "Obscurin, a giant sarcomeric Rho guanine nucleotide exchange factor
RT protein involved in sarcomere assembly.";
RL J. Cell Biol. 154:123-136(2001).

DR InterPro; IPR0033961; FN_III.
DR InterPro; IPR0033006; Ig_MHC.
DR InterPro; IPR0000048; IQ_region.

DR InterPro; IPR001412; tRNA-synt_L1.
DR Pfam; PF00041; fn3; 2.
DR Pfam; PF00047; lg; 49.

DR	Pfam; PF00169; PH; 1.			
DR	Pfam; PF00621; Rhogef; 1.			
DR	PROSITE; PS00178; AA_TRANSLIGASE_I; UNKNOWN_1.			
DR	PROSITE; PS50996; IO; 1.			
DR	PROSITE; PS50003; PH_DOMAIN; 1.			
SO	SEQUENCE 6620 AA; 721665 MW; C2AE8EB77B284452 CMC64;			
Query Match		14.48%;	Score 90;	DB 4; Length 6620;
Best Local Similarity		27.48%;	Pred. NO. 5.4;	

QY	6	DRAPDFLSPEDQVLRPALGSSVALNCTAMVYSGPHCLSPVQMLKGLPLIGIGHYSLH	65
		: : : : : : : : : : : :	
Db	5123	DAAVFLTELQNEVQD--GYVPSFDC---VYIQG--PMSVRFKFKGKLLLEEDDHMYIN	51
QY	66	EYSWKANLSEVLVSSYLGVNNTSTREYVGATFCSIQN	102
		: : : : : : : : : : : :	
Db	5176	E---DQGGHQLITIAVPEADM-----GVYRCIAEN	5203
RESULT 11			
ID	Q23550	PRELIMINARY:	PRF: 6831 AA.
DC	Q23550	Q23020: Q27232;	
DT	01-NOV-1996	(Tremblrel. 01, Created)	
DT	01-NOV-1998	(Tremblrel. 08, Last sequence update)	
DT	01-MAR-2002	(Tremblrel. 20, Last annotation update)	
DE	UNC-22 protein.		

05 *Caenorhabditis elegans*.
0C Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
0C Rhabditidae; Peloderinae; Caenorhabditis.

RN [1] _
 RP SEQUENCE FROM N.A.
 RA White S., Harris B.;
 RL submitted (NOV-1996) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE OF 784-6831 FROM N.A.
 RC STRAIN=BRISTOL N2;
 RC

RT "Sequence of an unusually large protein implicated in regulation of
RT myosin activity in *C. elegans*."
RL Nature 342:45-50(1989).
RN [3]
RP SEQUENCE OF 784-6831 FROM N.A.
RC STRAIN=BRISTOL N2;

[illegible]

CC ISOFORM SC26k17.1B (SHOWN HERE); MAY BE PRODUCED BY ALTERNATIVE SPLICING.

CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.

DR EMBL: Z73899; CAA98082.1; JOINED.

DR EMBL: Z73897; CAA98082.1; JOINED.

DR EMBL: Z73899; CAA98085.1; JOINED.

DR HSSP: Q63450.1A06.

DR Wormpep: ZK617.1B; CE06635.

DR InterPro: IPR000719; Euk_Pkinase.

DR InterPro: IPR003962; Fm11_repeat.

DR InterPro: IPR003961; Fm11.

DR InterPro: IPR003958; FN_c2.

DR InterPro: IPR003600; Ig_Like.

DR InterPro: IPR003606; Ig_MHC.

DR InterPro: IPR002290; Ser_thr_kinase.

DR InterPro: IPR001412; tRNA-synt_1.

DR Pfam: PF00047; fn3; 31.

DR Pfam: PF00069; Pkinase; 1.

DR PRINTS: PR00014; FNTYPEP11.

DR ProDom: PD000001; Euk_Pkinase; 1.

DR SMART: SM00060; FN3; 27.

DR SMART: SM00408; IGc2; 6.

DR SMART: SM00410; IG_Like; 18.

DR SMART: SM00220; S_TKC; 1.

DR PROSITE: PS00178; AA_TRNA_LIGASE_I; UNKNOWN_1.

DR PROSITE: PS00107; PROTEIN_KINASE_ATP; UNKNOWN_1.

DR PROSITE: PS50011; PROTEIN_KINASE_DOM; 1.

DR PROSITE: PS00108; PROTEIN_KINASE_ST; 1.

KW ATP-binding; Alternative splicing; Hypothetical protein; Immunoglobulin domain; Repeat; Serine/threonine-protein kinase;

KW Transferrase

SQ SEQUENCE 7160 AA: 789230 MW: 387D0M4F6Z7CD027 CRC64;

Query Match Similarity 14.4%; Score 90; DB 5; Length 7160;
Best Local 23; Conservative 21; Mismatches 40; Indels 12; Gaps 3;

Matches 23; Conserved 21; Mismatches 40; Indels 12; Gaps 3;

QY 7 RAPDFLSSEDDVLRPALGSSVALNCTMVVSGPHCSLPVSQWLKDGLPLICGHYSIHE 66
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 101 REPSPV--GKRPIIPDKDGALIVMCKV----KSASTPVAKMKMDGVPLSMGGLYHA-- 151
| :
QY 67 YSWKANISEVLNVSVLGAVNTSTEVYGAFTCSION 102
| :
Db 152 --IFSDLDGDQTYLCQLERGPSSSDAQYRCNIKN 184
| :

RESULT 13

OBSMW3 PRELIMINARY; PTR: 1036 AA.

AC OBSMW3;
ID OBSMW3;
DT 01-JUN-2002 (TREMBlrel. 21, Created)
DT 01-JUN-2002 (TREMBlrel. 21, Last sequence update)
DE 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
DE LD28757P.
GN CG1084.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-BERKELEY;
RA Stapleton M., Broksstein P., Hong L., Agabany A., Carlson J.,
RA Champe M., Chavez C., Dorsett V., Dresnek D., Farfan D., Frise E.,
RA Miranda R., Gonzalez W., Guan H., Krommiller B., Li P., Liao G.,
RA Andrade A., Mungaii C.J., Nunoo J., Pacleb J., Paragas V., Park S.,
RA Patel S., Phouanavong S., Wan K., Yu C., Lewis S.E., Rubin G.M.,
RA Ceiliker S.;
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
EMBL: AY095040; AACM1368.1; .

SO SEQUENCE 1036 AA; 117742 MW; A370F297D39D719D CRC64;
Query Match 14.1%; Score 88; DB 5; Length 1036;
Best Local Similarity 27.7%; Pred. No. 0.92;
Matches 28; Conservative 9; Mismatches 42; Indels 22; Gaps 4;
OY 4 VCDRAPDFLS-PSEDOVLRPALGSSVALNCTAMVVSQPHCS-LPSVQWLKDLPLIGIGH 61
DB 397 VLSMKPSFKKHLESEVY-----AVYNGNTTIVCDPEAPRPFKQMKKQGVIGSGGH 449
OY 62 YSLHEYSWKANLSEVLSVGVNTSTEVGAFTCSIQN 102
DB 450 -----RRLPSGTLTISPTSRDDEGIYTCIASN 477
RESULT 14
O9VN14 PRELIMINARY; PRT; 1336 AA.
O9VN14: 01-MAY-2000 (TREMBlrel. 13, Created)
DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)
DE CG1084 protein.
GN CG1084.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BERKELEY;
RX MEDLINE=20196006; PubMed=10731132;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galie R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.C., Wortman J.R., Vandeil M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.-H.C., Blazer R.G., Champagne M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA Abail J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotler P.,
RA Burris K.C., Busan D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
RA Foster C., Gabrielian A.E., Gary N.S., Gelbart W.M., Glasser K.,
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Helman T.J., Hernandez J.R., Houck J.,
RA Hoslin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwan C.,
RA Jaitai M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Lasako P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Maitel B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Paclele J.M.,
RA Palazolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.-Y., Wasserman D.A., Weinstock G.M., Weissbach J.,
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster.";
RL Science 287:2185-2195(2000).
DR EMBL; AF003606; AAF52137.1; -
DR HSSP; P20241; ICFB.

DR FlyBase: FBgn0037240; CG1084.
DR InterPro: IPR003961; FN.III.
DR InterPro: IPR003598; Ig_C2.
DR InterPro: IPR003600; Ig_1like.
DR InterPro: IPR003006; Ig_1MHC.
DR InterPro: IPR001304; Lectin_C.
DR Pfam: PF00047; fn3; 4.
DR Pfam: PF00047; Ig; 5.
DR Pfam: PF00059; Lectin_C; 1.
DR SMART: SM00034; CLEC7; 1.
DR SMART: SM00060; FN3; 4.
DR SMART: SM00408; IGC2; 3.
DR SMART: SM00410; IG_1like; 2.
DR PROSITE: PS50041; C_Type_Lectin_2; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 1336 AA; 151994 MW; 1636094A64484262 CRC64;
Query Match 14.1%; Score 88; DB 5; Length 1336;
Best Local Similarity 27.7%; Pred. No. 1.3;
Matches 28; Conservative 9; Mismatches 42; Indels 22; Gaps 4;
OY 4 VCDRAPDFLS-PSEDOVLRPALGSSVALNCTAMVVSQPHCS-LPSVQWLKDLPLIGIGH 61
DB 697 VLSMKPSFKKHLESEVY-----AVYNGNTTIVCDPEAPRPFKQMKKQGVIGSGGH 749
OY 62 YSLHEYSWKANLSEVLSVGVNTSTEVGAFTCSIQN 102
DB 750 -----RRLPSGTLTISPTSRDDEGIYTCIASN 777
RESULT 15
O96SC3 PRELIMINARY; PRT; 2673 AA.
O96SC3: 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DT 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
DE Fibulin-6 (Fragment).
GN FIBL-6.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=MELANOMA;
RA Kostka G., Timpl R.;
RT "Partial sequence of fibulin-6 with a c-terminal region related to
RT domain II and III of the fibulin family.";
RL Submitted (Apr-2001) to the EMBL/Genbank/DBJ databases.
DR EMBL; AJ306906; CAC37630.1; -
DR InterPro: IPR00152; Asx_hydroxyl.
DR InterPro: IPR000875; Cecropin.
DR InterPro: IPR000561; EGF_1like.
DR InterPro: IPR001881; EGF_Ca.
DR InterPro: IPR003006; Ig_1MHC.
DR InterPro: IPR000884; TSP1.
DR Pfam: PF00008; EGF; 5.
DR Pfam: PF00047; Ig; 17.
DR Pfam: PF00090; TSP_1; 6.
DR PROSITE: PS00010; ASX_HYDROXYL; UNKNOWN_5.
DR PROSITE: PS00268; CECROPIN; UNKNOWN_1.
DR PROSITE: PS01186; EGF_2; UNKNOWN_3.
DR PROSITE: PS01187; EGF_Ca; UNKNOWN_8.
DR PROSITE: PS50092; TSP1; 6.
FT NON_TER
SQ SEQUENCE 2673 AA; 291017 MW; BEAEC30B8340E272 CRC64;
Query Match 14.1%; Score 88; DB 4; Length 2673;
Best Local Similarity 28.6%; Pred. No. 2.9;
Matches 26; Conservative 13; Mismatches 32; Indels 20; Gaps 4;
OY 12 LSPSEDQVLRPALGSSVALNCTAMVVSQPHCS-LPSVQWLKDLPLIGIGHYSLHEYSWK 71

Mon Nov 18 09:59:22 2002

us-09-598-443-2_copy_1_118.rspt

Page 8

[illegible]

Search completed: November 14, 2002, 17:31:05
Job time : 42 secs